Statistical Methodology and Applications in Biostatistics
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M,
Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven BPL,
Tsushima T, Takeuchi H, Kato K, Kitagawa Y.
Evaluation of pathological complete response as a surrogate endpoint for overall survival in
resectable esophageal cancer.
British Journal of Surgery
2025;112(6): znaf131.
DOI: 10.1093/bjs/znaf131.
[Software]
Kondo M, Nagashima K, Isono S, Sato Y.
Weighted repeated measures correlation coefficient: A new correlation coefficient for handling missing
data with repeated measures.
Statistics in Medicine
2025;44(10–12): e70046.
DOI: 10.1002/sim.70046.
Gosho M, Ishii R, Nagashima K, Noma H, Maruo K.
Determining the prior mean in Bayesian logistic regression with sparse data: A non-arbitrary approach.
Journal of the Royal Statistical Society: Series C (Applied Statistics)
2025;74(1): 126–141.
DOI: 10.1093/jrsssc/qlae048.
Kimura R, Nomura S, Nagashima K, Sato Y.
Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a
randomised controlled trial using the minimisation method.
BMC Medical Research Methodology 2024;24(1):166.
DOI: 10.1186/s12874-024-02295-2.
Gosho M, Ohigashi T, Nagashima K, Ito Y, Maruo K.
Bias in odds ratios from logistic regression methods with sparse data set.
Journal of Epidemiology
2023;33(6):265–275.
DOI: 10.2188/jea.JE20210089.
Noma H, Nagashima K, Kato S, Teramukai S, Furukawa TA.
Flexible random-effects distribution models for meta-analysis.
Journal of Epidemiology
2022;32(10):441–448.
DOI: 10.2188/jea.JE20200376.
[arXiv:2003.04598]
Hamaguchi Y, Noma H, Nagashima K, Yamada T, Furukawa TA.
Frequentist performances of Bayesian prediction intervals for random-effects meta-analysis.
Biometrical Journal
2021;63(2):394–405.
DOI: 10.1002/bimj.201900351.
[arXiv:1907.00345]
Nagashima K, Noma H, Sato Y, Gosho M.
Sample size calculations for single-arm survival studies using transformations of the
Kaplan–Meier estimator.
Pharmaceutical Statistics
2021;20(3):499–511.
DOI: 10.1002/pst.2090.
[arXiv:2012.03355]
Nagashima K, Noma H, Furukawa TA.
Prediction intervals for random-effects meta-analysis: a confidence distribution approach.
Statistical Methods in Medical Research
2019;28(6):1689–1702.
DOI: 10.1177/0962280218773520.
[arXiv:1804.01054][Software]
Noma H, Nagashima K, Maruo K, Gosho M, Furukawa TA.
Bartlett-type corrections and bootstrap adjustments of likelihood-based inference methods for network
meta-analysis.
Statistics in Medicine
2018;37(7):1178–1190.
DOI: 10.1002/sim.7578.
Gosho M, Sato Y, Nagashima K, Takahashi S.
Trends in study design and the statistical methods employed in a leading general medicine journal.
Journal of Clinical Pharmacy and Therapeutics
2018;43(1):36–44.
DOI: 10.1111/jcpt.12605.
Sato Y, Gosho M, Nagashima K, Takahashi S, Ware JH, Laird NM.
Statistical methods in the Journal — an update.
New England Journal of Medicine
2017;376(11):1086–1087.
DOI: 10.1056/NEJMc1616211.
(Correspondence)
Nagashima K, Sato Y.
Information criteria for Firth's penalized partial likelihood approach in Cox regression models.
Statistics in Medicine
2017;36(21):3422–3436.
DOI: 10.1002/sim.7368.
[Postprint]
Noma H, Nagashima K.
A note on the Mantel–Haenszel estimators when the common effect assumptions are violated.
Epidemiologic Methods
2016;5(1):19–35.
DOI: 10.1515/em-2015-0004.
Nagashima K, Sato Y, Noma H, Hamada C.
An efficient and robust method for analyzing population pharmacokinetic data in genome-wide
pharmacogenomic studies: a generalized estimating equation approach.
Statistics in Medicine
2013;32(27):4838–4858.
DOI: 10.1002/sim.5895.
[arXiv:1805.05017]
Gosho M, Nagashima K, Sato Y.
Study designs and statistical analyses for biomarker research.
Sensors
2012;12(7):8966–8986.
DOI: 10.3390/s120708966. (Review)
Nagashima K, Sato Y, Hamada C.
A modified maximum contrast method for unequal sample sizes in pharmacogenomic studies.
Statistical Applications in Genetics and Molecular Biology
2011;10(1):Article 41.
DOI: 10.2202/1544-6115.1560.
[arXiv:2012.03475][Software]
Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim S-R,
Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada J-i, Yoshida T.
A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide
studies.
The Pharmacogenomics Journal
2009;9(2):137–146.
DOI: 10.1038/tpj.2008.17.
Medical Researches
Yamaoka K, Katsumata Y, Kohsaka S, Shiraishi Y, Kondo M, Nagashima K, Onoue T, Kataoka M, Watanabe T,
Nakashima D, Muramoto Y, Sato Y, Sato K, Nakamura M, Ieda M.
Patient-centered medical tools for sustained motivation in cardiac rehabilitation of patients with
heart failure: protocol of a multicenter randomized controlled trial (EXERCISE-HF trial).
Contemporary Clinical Trials Communications
2025. In press.
DOI: 10.1016/j.conctc.2025.101522.
Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M,
Tsuruoka N, Kasai T, Hata A.
Ripple effect of temporary self-sampling HPV test on screening uptake in the next round: A secondary
analysis of the ACCESS randomized controlled trial.
Journal of Medical Screening 2025.
In press.
DOI: 10.1177/09691413251352999.
Nagoshi N, Nagashima K, Okubo T, Ozaki M, Suzuki S, Takeda K, Iga T, Matsumoto M, Nakamura M, Watanabe
K.
How many cases of spinal intramedullary ependymoma surgery are required to achieve stability? -
Analysis using X-bar charts.
Spinal Cord
2025;63(7):372–376.
DOI: 10.1038/s41393-025-01090-0.
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Takeuchi M, Hirata K, Tsugaru K, Yamamoto S,
Nomura M, Tsushima T, Takeuchi H, Kato K, Kitagawa Y.
Investigating the synergistic effects of pembrolizumab and chemotherapy in gastric and
gastroesophageal junction cancer.
Journal of Gastric Cancer
2025;25(3):455–465.
DOI: 10.5230/jgc.2025.25.e33.
Hasegawa Y, Itokawa N, Kashiro A, Kitamura M, Nagashima K, Suzuki K, Higashi T, Shioda-Koyano K, Ono
H, Kawano T, Arai T, Kaneko K, Atsukawa M, Takeuchi K, Futagami S, Iwakiri K, Honda K.
Risk stratification for malignant potential of intraductal papillary mucinous neoplasms using the
apolipprotein-A2 isoforms blood test.
Clinical and Translational Gastroenterology
2025. In press.
DOI: 10.14309/ctg.0000000000000856.
Baba K, Suzuki N, Imamura CK, Booka E, Takahari D, Kawakami T, Kawakubo H, Kitagawa C, Kono Y, Ogura
K, Kito Y, Saito K, Yamamoto S, Takeuchi H, Kudo T, Tsunoda T, Mizukami T, Yamaguchi T, Shoji H, Saito
K, Tanoue K, Baba E, Nagashima K, Boku N.
A phase I/II trial evaluating the safety of increased-dose S-1 with oxaliplatin and nivolumab in
HER2-negative advanced gastric cancer.
BMC Cancer
2025;25:675.
DOI: 10.1186/s12885-025-14084-1.
Sado M, Nagashima K, Koreki A.
Scoring system for the Japanese version of the ICECAP-A.
Psychology Research and Behavior Management
2025;18:703–717.
DOI: 10.2147/PRBM.S480328.
Hoshino K, Iwasawa S, Yoshioka N, Suzuki S, Hashimoto I, Ukita S, Toshima G, Nagashima K, Takebayashi
T, Tsunoda M.
Increased risk of proximal tubular dysfunction due to occupational cadmium exposure: a
survival analysis study.
Journal of Occupational Health
2025;67(1):uiaf016.
DOI: 10.1093/joccuh/uiaf016.
Okui J*, Nagashima K*, Matsuda S*, Sato Y, Kawakubo H, Takeuchi M, Hirata K, Yamamoto S, Nomura M,
Tsushima T, Takeuchi H, Kato K, Kitagawa Y.
Investigating the synergistic effects of immunochemotherapy in esophageal squamous cell carcinoma.
Esophagus
2025;22(2):188–197.
DOI: 10.1007/s10388-025-01113-y.
(*equally contributed)
Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, Ishikawa K, Kaiho T,
Asaumi N, Baba T, Yamamoto S, Yokote K, The COMET Trial investigators.
Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: a randomised clinical
trial.
Diabetes, Obesity and Metabolism
2025;27(5):2473–2484.
DOI: 10.1111/dom.16244.
Hirano H, Takahashi N, Amanuma Y, Suzuki N, Takahari D, Kawakami T, Kudo-Saito C, Nagashima K, Boku N,
Kato K, Shoji H.
Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable
advanced or recurrent gastric cancer after progression on first-line treatment including
fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE).
BMC Cancer
2025;25(1):201.
DOI: 10.1186/s12885-025-13591-5.
Watanabe T, Oka H, Nagashima K, Nishi H, Kumai Y, Iijima H, Okami K, Shimizu Y, Kano S, Ito K,
Yamazaki T, Takahashi H, Oridate N, Yokota T, Koyama T, Kiyota N, Sato Y, Takahashi S, Kato K,
Kadowaki S, Honma Y.
Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and
nivolumab: a multicenter retrospective study.
The Oncologist
2025;30(3):oyaf018.
DOI: 10.1093/oncolo/oyaf018.
Ishida N, Harada S, Toki R, Hirata A, Matsumoto M, Miyagawa N, Iida M, Edagawa S, Miyake A, Kuwabara
K, Shibuki T, Kato S, Arakawa K, Kinoshita K, Sakurai-Yageta M, Tamiya G, Nagashima K, Muraoka H, Sato
Y, Takebayashi T.
Causal relationship between body mass index and insulin resistance: linear and nonlinear Mendelian
randomization study in a Japanese population.
Journal of Diabetes Investigation
2025;16(7):1305–1314.
DOI: 10.1111/jdi.14377.
Yamada Y, Seto Y, Yoshikawa T, Takeuchi H, Kitagawa Y, Kodera Y, Doki Y, Yoshida K, Muro K, Kabeya Y,
Kamada A, Nagashima K, Kumamaru H, Tachimori H, Sasako M, Katai H, Konno H, Kakeji Y.
Postoperative adjuvant chemotherapy in patients with gastric cancer based on the Nationwide Gastric
Cancer Registry in Japan.
Global Health & Medicine
2025;7(1):13–27.
DOI: 10.35772/ghm.2024.01080.
Yamaguchi R*, Oda T*, Nagashima K.
Comparison of the diagnostic accuracy of shear wave elastography with transient elastography in adult
nonalcoholic fatty liver disease: a systematic review and network meta-analysis of diagnostic test
accuracy.
Abdominal Radiology
2025;50(2):734–746.
DOI: 10.1007/s00261-024-04546-8.
(*equally contributed)
Inoue M, Ogasawara S, Kobayashi K, Okubo T, Itokawa N, Obu M, Fujimoto K, Unozawa H, Yumita S,
Fujiwara K, Nakagawa M, Kanzaki H, Koroki K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakamoto S,
Nagashima K, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Kato N.
Assessment of macrovascular invasion in advanced hepatocellular carcinoma: clinical implications and
treatment outcomes with systemic therapy.
Liver Cancer
2025;14(1):8–18.
DOI: 10.1159/000539380.
Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y,
Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Rika Kizawa R, Muro K, Aoki K, Boku N.
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer
(WJOG10417GTR study).
Journal for ImmunoTherapy of Cancer
2024;12(11):e010174.
DOI: 10.1136/jitc-2024-010174.
Matsuyama E, Miyata J, Terai H, Miyazaki N, Iwasaki T, Nagashima K, Watase M, Sunata K, Namkoong H,
Asakura T, Masaki K, Chubachi S, Ohgino K, Kawada I, Minami K, Hagiwara R, Ueda S, Yoshiyama T, Kokuto
H, Kusumoto T, Oashi A, Miyawaki M, Saito F, Tani T, Ishioka K, Takahashi S, Nakamura M, Ishii M, Sato
Y, Fukunaga K.
Chronic obstructive pulmonary disease, asthma, and mechanical ventilation are risk factors for dyspnea
in patients with long COVID: a Japanese nationwide cohort study.
Respiratory Investigation
2024;62(6):1094–1101.
DOI: 10.1016/j.resinv.2024.09.009.
Takaoka H, Kawada I, Hiruma G, Nagashima K, Terai H, Ishida N, Namkoong H, Asakura T, Masaki K,
Miyata J, Chubachi S, Ohgino K, Otsuka K, Miyao N, Odani T, Watase M, Baba R, Okamori S, Arai D,
Nakachi I, Kuwahara N, Fujiwara A, Okada T, Ishiguro T, Isono T, Ishii M, Sato Y, Fukunaga K.
Long COVID among the first three waves of COVID-19 in Japan: a multicentre cohort study.
BMJ Open Respiratory Research
2024;11(1):e002137.
DOI: 10.1136/bmjresp-2023-002137.
Yamaguchi T, Kumagai K, Yagi S, Nomura T, Nagashima K, Watanabe M, Makuuchi R, Kawakami K, Matsushima
T, Kadowaki S, Haruta S, Cho H, Kakihara N, Otsuka S, Yamada T, Imai Y, Fukunaga H, Boku N.
Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after
adjuvant chemotherapy with S-1 alone: A multicenter retrospective study.
Scientific Reports
2024;14(1):21854.
DOI: 10.1038/s41598-024-72423-x.
Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Morooka M, Ogushi M, Nagashima
K, Sato Y, Kuriyama N, Kuwabara S.
Multifocal motor neuropathy in Japan: A nationwide survey on prevalence, clinical profiles, and
treatment.
Muscle & Nerve
2024;70(5):1027–1033.
DOI: 10.1002/mus.28251.
Katsumata Y, Muramoto Y, Ishida N, Takemura R, Nagashima K, Ikoma T, Kawamatsu N, Araki M, Goda A,
Okawara H, Sawada T, Ichihara YK, Hattori O, Yamaoka K, Seki Y, Ryuzaki T, Ikura H, Nakashima D,
Nagura T, Nakamura M, Sato K, Shiraishi Y.
Sweat lactate sensor for detecting anaerobic threshold in heart failure: a prospective clinical trial
(LacS-001).
Scientific Reports
2024;14(1):18985.
DOI: 10.1038/s41598-024-70001-9.
Fujita M, Nagashima K, Uno T, Hashimoto H, Suzuki K, Kasai T, Yamaguchi K, Onouchi Y, Sato D, Fujisawa
T, Hata A.
Impact of the COVID-19 pandemic on hypofractionated radiotherapy use for breast cancer in Japan: a
nationwide study.
Advances in Radiation Oncology 2024;9(8):101555.
DOI: 10.1016/j.adro.2024.101555.
Hishikawa A, Nishimura ES, Yoshimoto N, Nakamichi R, Hama EY, Ito W, Maruki T, Nagashima K,
Shimizu-Hirota R, Takaishi H, Itoh H, Hayashi K.
Predicting exacerbation of renal function by DNA methylation clock and DNA damage of urinary shedding
cells: a pilot study.
Scientific Reports
2024;14(1):11530.
DOI: 10.1038/s41598-024-62405-4.
Yoshitake M, Sugiyama A, Shimohata T, Araki N, Suzuki M, Shibuya K, Nagashima K, Hattori N, Kuwabara
S.
Delivering the diagnosis of multiple system atrophy: A multicenter survey on Japanese neurologists'
perspectives.
BMC Neurology
2024;24(1):137–146.
DOI: 10.1186/s12883-024-03666-4.
Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M,
Tsuruoka N, Kasai T, Hata A.
Effectiveness of self-sampling human papillomavirus test on pre-cancer detection and screening uptake
in Japan: The ACCESS randomized controlled trial.
International Journal of Cancer 2024;155(5):905–915.
DOI: 10.1002/ijc.34970.
Uchida S, Uno S, Kondo M, Uwamino Y, Namkoong H, Nishimura T, Misawa K, Kashimura S, Yamato K,
Ishizaka T, Nagashima K, Kitagawa Y, Hasegawa N.
Factors affecting motivation for receiving a booster dose of the COVID-19 vaccine among Japanese
university students and staff: A cross-sectional questionnaire survey.
Scientific Reports 2024;14(1):8009.
DOI: 10.1038/s41598-024-58603-9.
Miyazaki N, Iwasaki T, Sakai H, Watanuki R, Tanizawa Y, Cai Z, Kawaguchi T, Tsurutani J, Nagashima K.
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor
receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis.
Current Medical Research and Opinion 2024;40(5):827–837.
DOI: 10.1080/03007995.2024.2332436.
Fujita M, Fujisawa T, Suzuki K, Nagashima K, Kasai T, Hashimoto H, Yamaguchi K, Onouchi Y, Sato D,
Hata A.
Impact of the coronavirus disease 2019 pandemic on primary and metastatic lung cancer treatments in
Japan: A nationwide study using an interrupted time series analysis.
Cancer Epidemiology 2024;90:102549. DOI: 10.1016/j.canep.2024.102549.
Fujita M, Yamaguchi K, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Onouchi Y, Sato D, Fujisawa T,
Hata A.
Impact of the COVID-19 pandemic on gastric surgery in Japan: A nationwide study using interrupted
time-series analyses.
Journal of Gastroenterology and Hepatology
2024;39(7):1277–1284.
DOI: 10.1111/jgh.16533.
Okada M, Ishida N, Kanzaki S, Kawada I, Nagashima K, Terai H, Hiruma G, Namkoong H, Asakura T, Masaki
K, Ohgino K, Miyata J, Chubachi S, Kodama N, Maeda S, Sakamoto S, Okamoto M, Nagasaki Y, Umeda A,
Miyagawa K, Shimada H, Minami K, Hagiwara R, Ishii M, Sato Y, Fukunaga K.
Upper respiratory symptoms as long COVID revealed through a cohort study of patients with COVID-19.
OTO Open 2024;8(1):e120. DOI: 10.1002/oto2.120.
Tsutsui K, Ukita S, Kondo M, Toshima G, Miyazaki N, Nagashima K, Ohmura M, Tsuchihashi S, Tsuji Y,
Katoh M, Aida N, Kobayashi Y, Ohtsu Y, Fujita Y, Tanaka S, Watanabe H, Naruse Y, Iizuka I, Kato H,
Mashimo Y, Senbonmatsu T.
Synergistic effect of motivation for the elderly and support for going out II; measures to induce
elderly men to go out.
Geriatrics 2024;9(1):21. DOI: 10.3390/geriatrics9010021.
Okui J*, Nagashima K*, Matsuda S*, Sato Y, Okamura A, Kawakubo H, Muto M, Kakeji Y, Kono K, Takeuchi
H, Watanabe M, Doki Y, Bamba T, Fukuda T, Fujiwara H, Sato S, Noma K, Miyata H, Fujita T, Kitagawa Y.
Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy
and surgery for oesophageal squamous cell carcinoma.
British Journal of Surgery 2024;111(2):znae038. DOI: 10.1093/bjs/znae038.
(*equally contributed)
Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Marie M, Ogushi M, Nagashima K,
Sato Y, Kuriyama N, Kuwabara S.
Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: A
nationwide survey study of 133 patients.
European Journal of Neurology 2024;31(5):e16249.
DOI: 10.1111/ene.16249.
Yamada Y, Nagashima K, Azuma M, Masutani M, Ichikawa H, Iwasa S, Takahashi N, Hirano H, Kanato K,
Machida N, Kinoshita T, Hata H, Kawakami H, Takahari D, Boku N, Kurokawa Y, Terashima M, Yoshikawa T,
Sekine S, Hiraoka N.
Predictive and prognostic value of excision repair cross-complementing group 1 in patients with
advanced gastric cancer.
BJC Reports 2024;
2: 18.
DOI: 10.1038/s44276-024-00046-w.
Kashiro A, Kobayashi M, Oh T, Miyamoto M, Atsumi J, Nagashima K, Takeuchi K, Nara S, Hijioka S,
Morizane C, Kikuchi S, Kato S, Kato K, Ochiai H, Obata D, Shizume Y, Konishi H, Nomura Y, Matsuyama K,
Xie C, Wong C, Huang Y, Jung G, Srivastava S, Kutsumi H, Honda K.
Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of
pancreatic cancer.
Journal of Gastroenterology 2024;
59(3): 263–278.
DOI: 10.1007/s00535-023-02072-w.
Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Morooka M, Ogushi M, Nagashima
K, Sato Y, Kuriyama N, Kuwabara S.
Prevalence, clinical profiles, and prognosis of CIDP in Japanese nationwide survey: analyses of 1257
diagnosis-confirmed patients.
Neurology
2024;102(6):e209130.
DOI: 10.1212/WNL.0000000000209130.
Kishimoto T, Kinoshita S, Kitazawa M, Hishimoto A, Asami T, Suda A, Bun S, Kikuchi T, Sado M, Takamiya
A, Mimura M, Sato Y, Takemura R, Nagashima K, Nakamae T, Abe Y, Kanazawa T, Kawabata Y, Tomita H, Abe
K, Hongo S, Kimura H, Sato A, Kida H, Sakuma K, Funayama M, Sugiyama N, Hino K, Amagai T, Takamiya M,
Kodama H, Goto K, Fujiwara S, Kaiya H, Nagao K, on behalf of the J-PROTECT collaborators.
Live two-way video versus face-to-face treatment for depression, anxiety, and obsessive-compulsive
disorder: A 24-week randomized controlled trial.
Psychiatry and Clinical Neurosciences 2024;
78(4): 220–228.
DOI: 10.1111/pcn.13618.
Shimozaki K, Nakayama I, Takahari D, Nagashima K, Yoshino K, Fukuda K, Fukuoka S, Osumi H, Ogura M,
Wakatsuki T, Ooki A, Shinozaki E, Chin K, Yamaguchi K.
Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for
HER2-positive advanced gastric cancer: a single-institution retrospective study.
Journal of Gastric Cancer
2023;23(4):e41.
DOI: 10.5230/jgc.2023.23.e41.
Nomura K, Kitagawa K, Tsuji M, Iida M, Aoki M, Miyauchi K, Hirayama J, Nagashima K, Takebayashi T,
Tsutsumi A.
The quantity and quality of scientific evidence about the health of working women in occupational
health of Japan: A scoping review.
Journal of Occupational Health
2023;65(1):e12427.
DOI: 10.1002/1348-9585.12427.
Terai H, Ishii M, Takemura R, Namkoong H, Shimamoto K, Masaki K, Tanosaki T, Chubachi S, Matsuyama E,
Hayashi R, Shimada T, Shigematsu L, Ito F, Kaji M, Takaoka H, Kurihara M, Nakagawara K, Tomiyasu S,
Sasahara K, Saito A, Otake S, Azegawa S, Okada M, Fukushima T, Morita A, Tanaka H, Sunata K, Asaoka M,
Nishie M, Shinozaki T, Ebisudani T, Akiyama Y, Mitsuishi A, Nakayama S, Ogawa T, Sakurai K, Irie M,
Yagi K, Ohgino K, Miyata J, Kabata H, Ikemura S, Kamata H, Yasuda H, Kawada I, Kimura R, Kondo M,
Iwasaki T, Ishida N, Hiruma G, Miyazaki N, Ishibashi Y, Harada S, Fujita T, Ito D, Bun S, Tabuchi H,
Kanzaki S, Shimizu E, Fukuda K, Yamagami J, Kobayashi K, Hirano T, Inoue T, Haraguchi M, Kagyo J,
Shiomi T, Lee H, Sugihara K, Omori N, Sayama K, Otsuka K, Miyao N, Odani T, Watase M, Mochimaru T,
Satomi R, Oyamada Y, Masuzawa K, Asakura T, Nakayama S, Suzuki Y, Baba R, Okamori S, Arai D, Nakachi
I, Kuwahara N, Fujiwara A, Okada T, Ishiguro T, Isono T, Mashimo S, Makino Y, Kaido T, Minematsu N,
Ueda S, Minami K, Hagiwara R, Manabe T, Fukui T, Funatsu Y, Koh H, Yoshiyama T, Kokuto H, Kusumoto T,
Oashi A, Miyawaki M, Saito F, Tani T, Ishioka K, Takahashi S, Nakamura M, Harada N, Sasano H, Goto A,
Kusaka Y, Ohba T, Nakano Y, Nishio K, Nakajima Y, Suzuki S, Yoshida S, Tateno H, Kodama N, Maeda S,
Sakamoto S, Okamoto M, Nagasaki Y, Umeda A, Miyagawa K, Shimada H, Hagimura K, Nagashima K, Sato T,
Sato Y, Hasegawa N, Takebayashi T, Nakahara J, Mimura M, Ogawa K, Shimmura S, Negishi K, Tsubota K,
Amagai M, Goto R, Ibuka Y, Kitagawa Y, Kanai T, Fukunaga K.
Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study.
Respiratory Investigation 2023;
61(6): 802–814.
DOI: 10.1016/j.resinv.2023.08.008.
[Preprint].
Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Machida E, Kohno T, Yatabe Y, Kanemitsu Y,
Hamamoto R, Takashima A, Shiraishi K, Sekine S.
A comprehensive appraisal of HER2 heterogeneity in
HER2-amplified and HER2-low colorectal cancer.
British Journal of Cancer
2023;129(7):1176–1183.
DOI: 10.1038/s41416-023-02382-z.
Takahashi N, Hara H, Nagashima K, Hirata K, Masuishi T, Matsumoto T, Kawakami H, Yamazaki K, Hironaka
S, Boku N, Muro K.
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus
trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric
junction adenocarcinoma (RETRIEVE study, WJOG15822G).
BMC Cancer 2023;
23(1): 726.
DOI: 10.1186/s12885-023-11199-1.
Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M,
Tsuruoka N, Kasai T, Hata A.
Acceptability of self-sampling human papillomavirus test for cervical cancer screening in Japan: A
questionnaire survey in the ACCESS trial.
PLoS ONE 2023;
18(6): e0286909.
DOI: 10.1371/journal.pone.0286909.
Fujita M, Yamaguchi K, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Onouchi Y, Sato D, Fujisawa T,
Hata A.
Changes in colorectal cancer treatment during the COVID-19 pandemic in Japan: interrupted time-series
analysis using the National Database of Japan.
Cancer Epidemiology 2023;
85: 102391.
DOI: 10.1016/j.canep.2023.102391.
Fujita M, Hashimoto H, Nagashima K, Suzuki K, Kasai T, Yamaguchi K, Onouchi Y, Sato D, Fujisawa T,
Hata A.
Impact of coronavirus disease 2019 pandemic on breast cancer surgery using the National Database of
Japan.
Scientific Reports 2023;
13(1): 4977.
DOI: 10.1038/s41598-023-32317-w.
Takahashi R, Uchiyama K, Washida N, Shibagaki K, Yanai A, Nakayama T, Nagashima K, Sato Y, Kanda T,
Itoh H.
Mean annual intradialytic blood pressure decline and cardiovascular events in Japanese patients on
maintenance hemodialysis.
Hypertension Research 2023;
46(6): 1536–1546.
DOI: 10.1038/s41440-023-01228-8.
Uwamino Y*, Nagashima K*, Yoshifuji A, Suga S, Nagao M, Fujisawa T, Ryuzaki M, Takemoto Y, Namkoong
H, Wakui M, Matsushita H, Hasegawa N, Sato Y, Murata M.
Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination.
npj Vaccines 2023;
8(1): 33.
DOI: 10.1038/s41541-023-00626-w.
(*equally contributed)
Kadono T, Iwasa S, Nagashima K, Oshima K, Yamamoto S, Hirano H, Okita N, Shoji H, Honma Y, Takashima
A, Kato K, Ushijima T, Boku N.
Progression patterns and site-specific responses in advanced gastric cancer patients treated with
nivolumab.
Cancer Medicine
2023; 12(8): 9322–9331.
DOI: 10.1002/cam4.5689.
Nakamura M, Ogawa R, Fujimori J, Uzawa A, Sato Y, Nagashima K, Kuriyama N, Kuwabara S, Nakashima I.
Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein
antibody-associated disease in a nationwide survey.
Multiple Sclerosis Journal
2023;29(4–5): 530–539.
DOI: 10.1177/13524585231156736.
Matsumura T, Ebigbo A, Römmele C, Ikematsu H, Ishigami H, Suzuki T, Harada H, Yada T, Takatori Y,
Takeuchi M, Okimoto K, Akizue N, Maruoka D, Kitagawa Y, Minamide T, Iwaki T, Amano Y, Matsusaka K,
Nagashima K, Maehata T, Yahagi N, Messmann H, Kato N.
Diagnostic value of adding magnifying chromoendoscopy to magnifying narrow-band imaging endoscopy for
colorectal polyps.
Clinical Gastroenterology and Hepatology
2023; 21(10): 2551–2559.e2.
DOI: 10.1016/j.cgh.2023.01.028.
Kubo A, Masugi Y, Hase T, Nagashima K, Kawai Y, Takizawa M, Hishiki T, Shiota M, Wakui M, Kitagawa Y,
Kabe Y, Sakamoto M, Yachie A, Hayashida T, Suematsu M.
Polysulfide serves as a hallmark of desmoplastic reaction to differentially diagnose ductal carcinoma
in situ and invasive breast cancer by SERS imaging.
Antioxidants 2023;
12(2): 240.
DOI: 10.3390/antiox12020240.
Kojima D, Washida N, Uchiyama K, Hama EY, Nagasaka T, Kusahana E, Nakayama T, Nagashima K, Sato Y,
Morimoto K, Kanda T, Itoh H.
The body mass index change is associated with death or hemodialysis transfer in Japanese patients
initiating peritoneal dialysis.
Renal Failure 2023;
45(1):2163904.
DOI: 10.1080/0886022X.2022.2163904.
Yamaguchi Y, Takashima A, Nagashima K, Kumagai K, Yamada T, Terashima M, Yabusaki H, Nishikawa K,
Tanabe K, Yunome G, Kawachi Y, Yamada T, Fukagawa T, Kinoshita T, Watanabe M, Ishiyama K, Inoue K,
Boku N.
Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric
cancer with synchronous oligo metastasis: a multicenter retrospective study.
Gastric Cancer
2023;26(2):307–316.
DOI: 10.1007/s10120-023-01363-8.
Fujita M, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Yamaguchi K, Onouchi Y, Sato D, Fujisawa T,
Hata A.
Changes in the number of cancer diagnosis practices due to the COVID-19 pandemic: interrupted
time-series analysis using the National Database of Japan.
Journal of Cancer Research and Clinical Oncology
2023;149(9):6023–6033.
DOI: 10.1007/s00432-022-04557-2.
Numasaki M, Ito K, Takagi K, Nagashima K, Notsuda H, Ogino H, Ando R, Tomioka Y, Suzuki T, Okada Y,
Nishioka Y, Unno M.
Diverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of
malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8.
Cellular Immunology
2023;383:104652.
DOI: 10.1016/j.cellimm.2022.104652.
Imamura S, Inagaki T, Abe M, Terada J, Kawasaki T, Nagashima K, Tatsumi K, Suzuki T.
Impaired dynamic response of oxygen saturation during the 6-min walk test is associated with mortality
in chronic fibrosing interstitial pneumonia.
Respiratory Care
2023;68(3):356–365.
DOI: 10.4187/respcare.10231
Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y,
Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y,
Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N.
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated
with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
Gastric Cancer
2023;26(1):132–144.
DOI: 10.1007/s10120-022-01349-y.
Tamura NT, Shikimoto R, Nagashima K, Sato Y, Nakagawa A, Irie S, Iwashita S, Mimura M, Fujisawa D.
Group multi-component programme based on cognitive behavioural therapy and positive psychology for
family caregivers of people with dementia: a randomised controlled study (3C study).
Psychogeriatrics
2023;23(1):141–156.
DOI: 10.1111/psyg.12919.
Ota Y, Nomura K, Fujita N, Suzuki T, Kamatsuka M, Sakata N, Nagashima K, Hirayama J, Fujita N, Shiga
K, Oyama N, Terada Y.
Influence of LINE-assisted provision of information about human papillomavirus and cervical cancer
prevention on HPV vaccine intention: A randomized controlled trial.
Vaccines
2022;10(12):2005.
DOI: 10.3390/vaccines10122005.
Yamada Y, Kobayashi H, Nagashima K, Sugihara K.
Real impact of oxaliplatin in adjuvant chemotherapy for patients with stage III colon cancer based on
the Multi-Institutional Registry of Large Bowel Cancer in Japan.
Global Health & Medicine
2022;4(5):259–267.
DOI: 10.35772/ghm.2022.01048.
Suzuki T, Ota Y, Sakata N, Fujita N, Kamatsuka M, Nagashima K, Hirayama J, Terada Y, Nomura K.
HPV vaccine intention among university students during suspension of active recommendation in Japan.
Human Vaccines & Immunotherapeutics
2022;18(6):2116900.
DOI: 10.1080/21645515.2022.2116900.
Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M,
Tsuruoka N, Kasai T, Hata A.
Implementation of a self-sampling HPV test for non-responders to cervical cancer screening in Japan:
secondary analysis of the ACCESS trial.
Scientific Reports
2022;12(1):14531.
DOI: 10.1038/s41598-022-18800-w.
Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y, Matsumoto T,
Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Takaishi H, Hamamoto Y, Muro K.
WJOG13219G: the efficacy and safety of FOLFOXIRI or doublet plus anti-VEGF therapy in previously
untreated BRAFV600E mutant metastatic colorectal
cancer: a multi-institutional registry-based study (BRACELET study).
Clinical Colorectal Cancer
2022;21(4):339–346.
DOI: 10.1016/j.clcc.2022.08.002.
Eriguchi T, Takeda A, Nemoto T, Tsurugai Y, Sanuki N, Tateishi Y, Kibe Y, Akiba T, Inoue M,
Nagashima K, Horita N.
Relationship between dose prescription methods and local control rate in stereotactic body
radiotherapy for early-stage non-small cell lung cancer: systematic review and meta-analysis.
Cancers
2022;14(15):3815.
DOI: 10.3390/cancers14153815.
Mashimo Y, Tsuchihashi S, Tsutsui K, Arai T, Tsuji Y, Numai T, Kameda K, Nishizawa K, Kobati M,
Tanaka S, Watanabe H, Naruse Y, Ohmura M, Ishida N, Iwasaki T, Hiruma G, Miyazaki N, Takemura R,
Nagashima K, Sato Y, Ohtsu Y, Nakano T, Aida N, Iizuka I, Kato H, Kobayashi Y, Senbonmatsu T.
Synergistic effect of motivation for the elderly and support for going out.
Journal of Personalized Medicine
2022;12(8):1257.
DOI: 10.3390/jpm12081257.
Ito T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima
H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Saruta M, Otsu S, Shinozaki K, Fujiwara T, Tamura T,
Baba E, Shiozawa M, Denda T, Ueno H, Nagashima K, Shimada Y.
Primary tumor location as a predictor of survival in patients with
RAS wild-type colorectal cancer who receive molecularly
targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese
Society for Cancer of the Colon and Rectum.
International Journal of Clinical Oncology
2022;27(9):1450–1458.
DOI: 10.1007/s10147-022-02208-7.
Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Yatabe Y, Shida D, Hamamoto R, Kleeman
SO, Leedham SJ, Maughan T, Takashima A, Shiraishi K, Sekine S.
Clinicopathological and molecular characteristics of RSPO
fusion-positive colorectal cancer.
British Journal of Cancer
2022;127(6):1043–1050.
DOI: 10.1038/s41416-022-01880-w.
Watanabe K, Shibuya K, Misawa S, Nagashima K, Suzuki Y-i, Suichi T, Kojima Y, Nakamura K, Kano H,
Prado M, Uzawaa A, Kuwabara S.
Impaired neuromuscular transmission in facial muscles of amyotrophic lateral sclerosis: A single-fiber
electromyography study.
Neurology and Clinical Neuroscience
2022;10(2):78–82.
DOI: 10.1111/ncn3.12580.
Fujita M, Shimazu M, Nagashima K, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Shozu M, Hanaoka H,
Tsuruoka N, Kasai T, Hata A.
Study protocol of the ACCESS trial: A randomized trial to evaluate the effectiveness of human
papillomavirus testing by self-sampling in cervical cancer screening uptake
and precancer detection.
BMJ Open
2022;12(2):e049803.
DOI: 10.1136/bmjopen-2021-049803.
Noro R, Honda K, Nagashima K, Motoi N, Kunugi S, Matsubayashi J, Takeuchi S, Shiraishi H, Okano T,
Kashiro A, Meng X, Yoshida Y, Watanabe S-i, Usuda J, Inoue T, Wilber H, Ikeda N, Seike M, Gemma A,
Kubota K.
Alpha-actinin-4 (ACTN4) gene amplification is a predictive
biomarker for adjuvant chemotherapy with UFT in stage I lung adenocarcinomas.
Cancer Science
2022;113(3):1002–1009.
DOI: 10.1111/cas.15228.
Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto
N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki
K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S,
Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y,
Kato N.
Evolution of survival impact of molecular target agents in patients with advanced hepatocellular
carcinoma.
Liver Cancer
2022;11(1):48–60.
DOI: 10.1159/000519868.
Hasegawa T, Seo T, Kubota Y, Sudo T, Yokota K, Miyazaki N, Muranaka A, Hirano S, Yamauchi A,
Nagashima K, Iyo M, Sakai I.
Reliability and validity of the Japanese version of the 4A's Test for delirium screening in the
elderly patient.
Asian Journal of Psychiatry
2022;67:102918.
DOI: 10.1016/j.ajp.2021.102918.
Felix K*, Honda K*, Nagashima K, Kashiro A, Takeuchi K, Kobayashi T, Hinterkopf S, Gaida MM, Dang H,
Brindl N, Kaiser J, Büchler MW, Strobel O.
Non-invasive risk stratification of IPMN with malignant potential by serum apolipoprotein-A2-isoforms.
International Journal of Cancer
2022;150(5):881–894.
DOI: 10.1002/ijc.33875.
(*equally contributed)
Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y,
Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N.
Second-line chemotherapy after early disease progression during first-line chemotherapy containing
bevacizumab for patients with metastatic colorectal cancer.
BMC Cancer
2021;21(1):1159.
DOI: 10.1186/s12885-021-08890-6.
Shoji H, Takahari D, Hara H, Nagashima K, Adachi J, Boku N.
A phase I study of pevonedistat plus CapeOX in patients with advanced gastric cancer refractory to
platinum (NCCH-1811).
Future Science OA
2021;7(7):FSO721.
DOI: 10.2144/fsoa-2021-0023.
Honda K, Hishiki T, Yamamoto S, Yamamoto T, Miura N, Kubo A, Itoh M, Chen W-Y, Takano M, Yoshikawa
T, Kasamatsu T, Sonoda S, Yoshizawa H, Nakamura S, Itai Y, Shiota M, Koike D, Naya M, Hayakawa N,
Naito Y, Matsuura T, Iwaisako K, Masui T, Uemoto S, Nagashima K, Hashimoto Y, Sakuma T, Matsubara O,
Huang W, Ida T, Akaike T, Masugi Y, Sakamoto M, Kato T, Ino Y, Yoshida H, Tsuda H, Hiraoka N, Kabe
Y, Suematsu M.
On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with
ovarian cancer to predict post-operative chemosensitivity.
Redox Biology
2021;41:101926.
DOI: 10.1016/j.redox.2021.101926.
Iwase M, Matsuura Y, Kuniyoshi K, Suzuki T, Nagashima K, Ohtori S.
Biomechanical evaluation of opponenplasty for low median palsy: a cadaver study.
Journal of Hand Surgery Global Online
2021;3(2):74–80.
DOI: 10.1016/j.jhsg.2020.11.002.
Yamaguchi T, Takashima A, Nagashima K, Terashima M, Aizawa M, Ohashi M, Tanaka R, Yamada T,
Kinoshita T, Inada T, Ishiyama K, Ema A, Yuasa Y, Haruta S, Kakihara N, Nishikawa K, Yunome G, Satoh
T, Fukagawa T, Katai H, Boku N.
Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal
metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis
(P1a): A multi-institutional retrospective study.
Gastric Cancer
2021;24(3):701–709. DOI: 10.1007/s10120-020-01137-6.
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh
H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E,
Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R,
Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, on behalf of the PRIME-V study
group.
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in
Japanese patients with type 2 diabetes mellitus: Sub-analysis of a prospective, randomized,
controlled study (PRIME-V study).
Journal of Diabetes Investigation
2021;12(2):200–206.
DOI: 10.1111/jdi.13340.
Sato Y, Kobayashi T, Nishiumi S, Okada A, Fujita T, Sanuki T, Kobayashi M, Asahara M, Adachi M,
Sakai A, Shiomi H, Masuda A, Yoshida M, Takeuchi K, Kodama Y, Kutsumi H, Nagashima K, Honda K.
Prospective study using plasma apolipoprotein A2-isoforms to screen for high-risk status of
pancreatic cancer. Cancers
2020;12(9):2625.
DOI: 10.3390/cancers12092625.
Nomura K, Minamizono S, Nagashima K, Ono M, Kitano N.
Maternal body mass index and breastfeeding non-initiation and cessation: a quantitative review of the
literature.
Nutrients
2020;12(9):2684.
DOI: 10.3390/nu12092684.
Imamura S, Inagaki T, Terada J, Nagashima K, Katsura H, Tatsumi K.
Long-term efficacy of pulmonary rehabilitation with home-based or low frequent maintenance programs in
patients with chronic obstructive pulmonary disease: a meta-analysis.
Annals of Palliative Medicine
2020;9(5):2606–2615.
DOI: 10.21037/apm-19-581.
Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, Asaumi N, Arai M,
Shimada F, Tachibana K, Watanabe Y, Ishikawa K, Hoshino A, Yamamoto K, Kubota-Taniai M, Mayama T,
Yamamoto S, Yokote K.
Safety and efficacy of ranibizumab and luseogliflozin combination therapy in diabetic macular edema
patients: protocol for a multicenter, randomized controlled, open-label
trial. Diabetes Therapy
2020;11(8):1891–1905.
DOI: 10.1007/s13300-020-00854-6.
Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura
T, Kuroda H, Ohki T, Nagashima K, Ooka Y, Takita M, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato
N, Kudo M, Omata M.
Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular
carcinoma.
Liver Cancer
2020;9(5):583–595.
DOI: 10.1159/000508724.
Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Nagashima K, Aoki K, Mizoguchi Y,
Kitano S, Yachida S, Shiba S, Kitagawa Y.
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER
(JCOG1804E).
Future Oncology
2020;16(19):1351–1357.
DOI: 10.2217/fon-2020-0189.
Nagata Y, Kato K, Miyamoto T, Hirano H, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T,
Matsushita H, Nagashima K, Saruta M, Boku N.
Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in
gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy.
Supportive Care in Cancer
2020;28(12):5861–5869. 10.1007/s00520-020-05401-4.
Katsumata Y, Terada J, Matsumura T, Koshikawa K, Sakao S, Tomiyoshi G, Shinmen N, Nakamura R, Kuroda
H, Nagashima K, Kobayashi Y, Kobayashi E, Iwadate Y, Zhang X-M, Hiwasa T, Tatsumi K.
Circulating anti-sorting nexins 16 antibodies as an emerging biomarker of coronary artery disease in
patients with obstructive sleep apnea.
Diagnostics
2020;10(2):71.
DOI: 10.3390/diagnostics10020071.
Suichi T, Misawa S, Nagashima K, Sato Y, Iwai Y, Katayama K, Sekiguchi Y, Shibuya K, Amino H, Suzuki
Y-i, Tsuneyama A, Nakamura K, Kuwabara S.
Lenalidomide treatment for thalidomide-refractory POEMS syndrome: A prospective single-arm clinical
trial.
Internal Medicine
2020;59(9):1149–1153.
DOI: 10.2169/internalmedicine.3800-19.
Ishikawa M, Iwasa S, Aoki M, Imazeki H, Hirano H, Shoji H, Honma Y, Okita N, Nagashima K, Takashima
A, Kato K, Saruta M, Boku N.
Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as
second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Investigational New Drugs
2020;38(2):533–540.
DOI: 10.1007/s10637-019-00822-3.
Iwase T, Sangai T, Fujimoto H, Sawabe Y, Matsushita K, Nagashima K, Sato Y, Nakagawa A, Masuda T,
Nagashima T, Ohtsuka M.
Quality and quantity of visceral fat tissue are associated with insulin resistance and survival
outcomes after chemotherapy in patients with breast cancer.
Breast Cancer Research and Treatment
2020;179(2):435–443.
DOI: 10.1007/s10549-019-05467-7.
Satomi NT, Honma Y, Nagashima K, Umezawa R, Ito Y, Hirano H, Shoji H, Takashima A, Iwasa S, Kato K,
Hamaguchi T, Itami J, Boku N.
Risk factors of severe benign cicatricial stricture after definitive chemoradiation for localized T3
esophageal carcinoma.
Anticancer Research
2020;40(2):1071–1077.
DOI: 10.21873/anticanres.14045.
Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N,
Inaba K, Ito Y, Itami J, Kanamori J, Oguma J, Daiko H.
Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with
chemoradiotherapy.
Cancer Medicine
2020;9(2):595–604.
DOI: 10.1002/cam4.2708.
Fujita M, Nagashima K, Takahashi S, Suzuki K, Fujisawa T, Hata A.
Hand-held flow meter improves COPD detectability regardless of using a conventional questionnaire: a
split-sample validation study.
Respirology
2020;25(2):191–197.
DOI: 10.1111/resp.13602.
Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, Tashiro K, Yamada T,
Kinoshita T, Hata H, Kawachi Y, Kawabata R, Tsuji T, Hihara J, Sakamoto T, Fukagawa T, Katai H,
Higuchi K, Boku N.
Efficacy of post-operative chemotherapy after resection leaving no macroscopically visible disease of
gastric cancer with peritoneal lavage cytology positive (CY1) or localized peritoneum metastasis
(P1a): a multicenter retrospective study.
Annals of Surgical Oncology
2020;27(1):284–292.
DOI: 10.1245/s10434-019-07697-x.
Nomura K, Nagashima K, Suzuki T, Itoh H.
Application of Japanese guidelines for gestational weight gain to multiple pregnancy outcomes and its
optimal range in 101,336 Japanese women.
Scientific Reports
2019;9(1):17310.
DOI: 10.1038/s41598-019-53809-8.
Masuda K, Shoji H, Nagashima K, Yamamoto S, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa
S, Okita N, Takashima A, Kato K, Boku N.
Correlation between immune-related adverse events and prognosis in patients with gastric cancer
treated with nivolumab.
BMC Cancer
2019;19(1):974.
DOI: 10.1186/s12885-019-6150-y.
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi
T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K,
Habuchi T.
Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed
metastatic prostate cancer initially treated with androgen deprivation therapy.
Cancer Medicine
2019;8(15):6566–6577.
DOI: 10.1002/cam4.2502.
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi
T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K,
Habuchi T.
Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed
metastatic prostate cancer.
Scientific Reports
2019;9(1):12071.
DOI: 10.1038/s41598-019-48600-8.
Monma S, Kato K, Shouji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y,
Boku N, Nagashima K, Ito Y, Itami J.
Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced
esophageal cancer.
Esophagus
2019;16(4):402–407.
DOI: 10.1007/s10388-019-00680-1.
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh
H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E,
Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R,
Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, On behalf of the PRIME-V study
group.
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic
dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective,
multicentre, open-label, blinded-endpoint, randomised controlled study (PRIME-V study).
Diabetes, Obesity and Metabolism
2019;21(8):1990–1995.
DOI: 10.1111/dom.13750.
Fujita M, Nagashima K, Takahashi S, Hata A.
Inequality within a community at the neighborhood level and the incidence of mood disorders in Japan:
a multilevel analysis.
Social Psychiatry and Psychiatric Epidemiology
2019;54(9):1125–1131.
DOI: 10.1007/s00127-019-01687-w.
Aoki M, Shoji H, Nagashima K, Imazeki H, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima
A, Kato K, Higuchi K, Boku N.
Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric
cancer.
ESMO Open
2019;4:e000488.
DOI: 10.1136/esmoopen-2019-000488.
Matsumura T, Terada J, Yoshimura C, Koshikawa K, Kinoshita T, Yahaba M, Nagashima K, Sakao S,
Tatsumi K.
Single-use suvorexant for treating insomnia during overnight polysomnography in patients with
suspected obstructive sleep apnea: a single-center experience.
Drug Design, Development and Therapy
2019;13:809–816.
DOI: 10.2147/DDDT.S197237.
Hiramoto S, Tamaki T, Nagashima K, Hori T, Kikuchi A, Yoshioka A, Inoue A.
Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer.
International Journal of Clinical Oncology
2019;24(4):454–459.
DOI: 10.1007/s10147-018-1363-7.
Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara
H, Tanaka Y, Saito Y, Nagashima K, Igaki H.
Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus
5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell
carcinoma.
International Journal of Clinical Oncology
2019;24(1):60–67.
DOI: 10.1007/s10147-018-1336-x.
Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T,
Boku N, Shimada Y, Yamada Y.
Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission
tomography/computed tomography: a proof-of-concept study.
British Journal of Radiology
2018;91(1089):20180259.
DOI: 10.1259/bjr.20180259.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A.
Medical costs attributable to overweight and obesity in Japanese individuals.
Obesity Research & Clinical Practice
2018;12(5):479–484.
DOI: 10.1016/j.orcp.2018.06.002.
Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Nagashima K, Hanaoka H, Kobayashi Y.
Intravenous nicorandil versus adenosine for fractional flow reserve measurement: A crossover,
randomized study.
Heart and Vessels
2018;33(12):1570–1575.
DOI: 10.1007/s00380-018-1197-2.
Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H,
Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H,
Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K-i, Takazaki H, Suzuki N, Suzuki
S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, for the Japanese Eculizumab Trial
for GBS (JET-GBS) Study Group.
Safety and efficacy of eculizumab in Guillain–Barré syndrome: a multicentre,
double-blind, randomised phase 2 trial.
The Lancet Neurology
2018;17(6):519–529.
DOI: 10.1016/S1474-4422(18)30114-5.
Fujita M, Sugiyama M, Sato Y, Nagashima K, Takahashi S, Mizogami M, Hata A.
Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National
Database of Japan.
Journal of Viral Hepatitis
2018;25(11):1312–1320.
DOI: 10.1111/jvh.12933.
Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Tsushima K, Sakao S, Nagashima K, Ozaki T,
Kobayashi Y, Hiwasa T, Tatsumi K.
Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): a potential
biomarker for coronary artery disease in patients with obstructive sleep apnea.
PLoS ONE
2018;13(3):e0195015.
DOI: 10.1371/journal.pone.0195015.
Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku
N, Higuchi K.
Type of second primary malignancy after achieving complete response by definitive chemoradiation
therapy in patients with esophageal squamous cell carcinoma.
International Journal of Clinical Oncology
2018;23(4):652–658.
DOI: 10.1007/s10147-018-1258-7.
Watanabe K, Hirano S, Kojima K, Nagashima K, Mukai H, Sato T, Takemoto M, Matsumoto K, Iimori T,
Isose S, Omori S, Shibuya K, Sekiguchi Y, Beppu M, Amino H, Suichi T, Yokote K, Uno T, Kuwabara S,
Misawa S.
Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain.
Journal of Neurology, Neurosurgery, and Psychiatry
2018;89(10):1082–1087.
DOI: 10.1136/jnnp-2017-316601.
Kotooka N, Kitakaze M, Nagashima K, Asaka M, Kinugasa Y, Nochioka K, Mizuno A, Nagatomo D, Mine D,
Yamada Y, Kuratomi A, Okada N, Fujimatsu D, Kuwahata S, Toyoda S, Hirotani S-i, Komori T, Eguchi K,
Kario K, Inomata T, Sugi K, Yamamoto K, Tsutsui H, Masuyama T, Shimokawa H, Momomura S-i, Seino Y,
Sato Y, Inoue T, Node K, On behalf of the HOMES-HF study investigators.
The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with
heart failure: home telemonitoring study for patients with heart failure (HOMES-HF).
Heart and Vessels
2018;33(8):866–876.
DOI: 10.1007/s00380-018-1133-5.
Inagaki T, Terada J, Yahaba M, Kawata N, Jujo T, Nagashima K, Sakao S, Tanabe N, Tatsumi K.
Heart rate and oxygen saturation change patterns during 6-min walk test in subjects with chronic
thromboembolic pulmonary hypertension.
Respiratory Care
2018;63(5):573–583.
DOI: 10.4187/respcare.05788.
Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y,
Takashima A, Kato K, Hamaguchi T.
A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced
gastric cancer.
Gastric Cancer
2018;21(3):439–445.
DOI: 10.1007/s10120-017-0753-2.
Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T,
Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N.
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis
of emesis induced by highly emetogenic cisplatin-based chemotherapy.
International Journal of Clinical Oncology
2018;23(2):382–388.
DOI: 10.1007/s10147-017-1200-4.
Kinoshita T, Yahaba M, Terada J, Matsumura T, Sakurai Y, Sakao S, Nagashima K, Tatsumi K.
Impact of arterial stiffness on WatchPAT variables in patients with obstructive sleep apnea.
Journal of Clinical Sleep Medicine
2018;14(3):319–325.
DOI: 10.5664/jcsm.6970.
Korematsu S, Nagashima K, Sato Y, Nagao M, Hasegawa S, Nakamura H, Sugiura S, Miura K, Okada K,
Fujisawa T.
"Spike" in acute asthma exacerbations during enterovirus D68 epidemic in Japan: A nation-wide survey.
Allergology International
2018;67(1):55–60.
DOI: 10.1016/j.alit.2017.04.003.
Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, Yasui H, Matsushima T, Takahari D,
Nagashima K, Boku N.
Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet
chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Cancer Chemotherapy and Pharmacology
2017;80(3):575–582.
DOI: 10.1007/s00280-017-3397-3.
Shiraishi H, Fujiwara Y, Kakuya T, Tsuta K, Motoi N, Miura N, Watabe Y, Watanabe S-i, Noro R,
Nagashima K, Huang W, Yamada T, Asamura H, Ohe Y, Honda K.
Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung
adenocarcinoma.
Biomarkers in Medicine
2017;11(9):721–731.
DOI: 10.2217/bmm-2017-0150.
Honma Y, Hokamura N, Nagashima K, Sudo K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku
N, Ito Y, Itami J, Koyanagi K, Igaki H, Tachimori Y.
Clinical outcomes of resectable esophageal cancer with supraclavicular lymph node metastases treated
with curative intent.
Anticancer Research
2017;37(7):3741–3749.
DOI: 10.21873/anticanres.11748.
Nishide A, Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A.
Income-related inequalities in access to dental care services in Japan.
International Journal of Environmental Research and
Public Health
2017;14(5):524.
DOI: 10.3390/ijerph14050524.
Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y,
Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Hamaguchi T.
The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival
in advanced gastric cancer patients receiving cisplatin-based chemotherapy.
Oncotarget
2017;8(56):95083–95094.
DOI: 10.18632/oncotarget.18297.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A.
Impact of geographic accessibility on utilization of the annual health check-ups by income level in
Japan: A multilevel analysis.
PLoS ONE
2017;12(5):e0177091.
DOI: 10.1371/journal.pone.0177091.
Nomura K, Kido M, Tanabe A, Nagashima K, Takenoshita S, Ando K.
Investigation of optimal weight gain during pregnancy for Japanese Women.
Scientific Reports
2017;7(1):2569.
DOI: 10.1038/s41598-017-02863-1.
Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Ema R, Amata A, Sakao S, Nagashima K,
Tatsumi K, Hiwasa T.
Circulating anti-coatomer protein complex subunit epsilon (COPE) autoantibodies as a potential
biomarker for cardiovascular and cerebrovascular events in patients with obstructive sleep apnea.
Journal of Clinical Sleep Medicine
2017;13(3):393–400.
DOI: 10.5664/jcsm.6488.
Koshizaka M, Ishikawa K, Ishikawa T, Kobayashi K, Takemoto M, Horikoshi T, Shimousa R, Takahashi S,
Nagashima K, Sato Y, Tatsuno I, Terano T, Hashimoto N, Kuribayashi N, Uchida D, Yokote K, on behalf
of the PRIME-V Study Investigators.
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in type 2 diabetes
patients receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: A study protocol for a
prospective, multicenter, blinded-endpoint phase IV randomized controlled trial (PRIME-V study).
BMJ Open
2017;7(5):e015766.
DOI: 10.1136/bmjopen-2016-015766.
Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y,
Shimada Y, Boku N.
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to
fluoropyrimidines, platinum, and taxanes.
Gastric Cancer
2017;20(4):655–662.
DOI: 10.1007/s10120-016-0670-9.
Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Akagi R, Yamaguchi T, Takahashi K, Nagashima
K, Takahashi K.
Quantitative US elastography can be used to quantify mechanical and histologic tendon healing in a
rabbit model of achilles tendon transection.
Radiology
2017;283(2):408–417.
DOI: 10.1148/radiol.2016160695.
Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T,
Yokota T, Nishida Y, Kohara N, Hirata K, Nishiyama K, Yabe I, Kaida K-I, Suzuki N, Nodera H, Tsuji
S, Koike H, Kira J-I, Hanaoka H, Kusunoki S, Kuwabara S, JET-GBS Group.
A prospective, multi-center, randomized phase II study to evaluate the efficacy and safety of
eculizumab in patients with Guillain-Barré syndrome (GBS): Japanese Eculizumab Trial for GBS
(JET-GBS).
JMIR Research Protocols
2016;5(4):e210.
DOI: 10.2196/resprot.6610.
Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Sugimoto K, Nagashima K, Hanaoka H, Kobayashi Y.
Efficacy of intravenous nicorandil for fractional flow reserve assessment: Study protocol for a
crossover randomised trial.
BMJ Open
2016;6(11):e012737.
DOI: 10.1136/bmjopen-2016-012737.
Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki
H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I,
Ikeda S-i, Kohara N, Kanda T, Kira J-i, Hanaoka H, Kuwabara S, for the Japanese POEMS Syndrome for
Thalidomide (J-POST) Trial Study Group.
Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised,
double-blind, placebo-controlled trial.
The Lancet Neurology
2016;15(11):1129–1137.
DOI: 10.1016/S1474-4422(16)30157-0.
Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S,
Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T.
Pretreatment immune status correlates with progression-free survival in chemotherapy-treated
metastatic colorectal cancer patients.
Cancer Immunology Research
2016;4(7):592–599.
DOI: 10.1158/2326-6066.CIR-15-0298.
Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Ohue
M, Nagashima K, Yamada Y.
Prognostic and predictive value of extended RAS mutation and
mismatch repair status in stage III colorectal cancer.
Cancer Science
2016;107(7):1006–1012.
DOI: 10.1111/cas.12950.
Tanemura N, Uyama Y, Nagashima K, Suzuki T, Asahina Y, Kobayashi Y, Iyo M, Yokote K, Hanaoka H.
Comparison of drug use between clinical practice and regulatory approval: results in older Japanese
patients with rheumatoid arthritis, diabetes, high blood pressure, or depression.
Therapeutic Innovation & Regulatory Science
2016;50(6):743–750.
DOI: 10.1177/2168479016648731.
Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi T, Shoji H, Honma Y, Takashima A, Okita N,
Kato K, Yamada Y, Shimada Y.
Comparison of panitumumab plus irinotecan and cetuximab plus irinotecan for
KRAS wild-type metastatic colorectal cancer.
Anticancer Research
2016;36(7):3531–3536.
URL: http://ar.iiarjournals.org/content/36/7/3531.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A.
Income related inequality of health care access in Japan: A retrospective cohort study.
PLoS ONE
2016;11(3):e0151690.
DOI: 10.1371/journal.pone.0151690.
Tawada A, Chiba T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Arai M, Kanda T, Shinozaki M, Goto N,
Nagashima K, Yokosuka O.
Utility of prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated
with nucleos(t)ide analogues.
Oncology
2016;90(4):199–208.
DOI: 10.1159/000444392.
Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Nagashima K, Takahashi K.
Quantitative ultrasound elastography with an acoustic coupler for achilles tendon elasticity:
measurement repeatability and normative values.
Journal of Ultrasound in Medicine
2016;35(1):159–166.
DOI: 10.7863/ultra.14.11042.
Naito S, Tanaka J, Nagashima K, Chang B, Hishiki H, Takahashi Y, Oikawa J, Nagasawa K, Shimojo N,
Ishiwada N.
The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood
community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan.
Epidemiology and Infection
2016;144(3):494–506.
DOI: 10.1017/S0950268815001272.
Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka
H, Hata A, on behalf of the KAICA Trial investigators.
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to
evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki
disease (KAICA Trial).
BMJ Open
2015;5(12):e009562.
DOI: 10.1136/bmjopen-2015-009562.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A.
Validity assessment of self-reported medication use by comparing to pharmacy insurance claims.
BMJ Open
2015;5(11):e009490.
DOI: 10.1136/bmjopen-2015-009490.
Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita N,
Shimada Y, Yamada Y.
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin
with or without bevacizumab in metastatic colorectal cancer: a pooled
analysis of four phase II studies.
Cancer Chemotherapy and Pharmacology
2015;76(3):605–614.
DOI: 10.1007/s00280-015-2834-4.
Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A.
Predictive power of a body shape index for development of diabetes, hypertension, and dyslipidemia in
Japanese adults: a retrospective cohort study.
PLoS ONE
2015;10(6):e0128972.
DOI: 10.1371/journal.pone.0128972.
Utsumi H, Honma Y, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T, Yamada Y, Shimada Y,
Kishi Y, Nara S, Esaki M, Shimada K.
Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal
cancer.
Anticancer Research
2015;35(4):2255–2261.
URL: http://ar.iiarjournals.org/content/35/4/2255.
Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N,
Takashima A, Kato K, Hamaguchi T, Shimada Y.
Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor
antibody in metastatic colorectal cancer.
Cancer Science
2015;106(5):604–610.
DOI: 10.1111/cas.12642.
Nagashima K, Yanai T, Iwasa S, Ohyanagi F, Kasai T, Minato K, Sakai H, Sakamoto C, Takeda K, Harada
D, Goto K, Yamamoto N.
A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly
emetogenic chemotherapy.
Japanese Journal of Clinical Oncology
2015;75(2):229–231.
DOI: 10.1093/jjco/hyu191.
Shirakawa T, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y,
Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y.
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal
squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Cancer Chemotherapy and Pharmacology
2014;74(6):1207–1215.
DOI: 10.1007/s00280-014-2597-3.
Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima S, Honma Y, Iwasa S, Kato K,
Hamaguchi T, Shimada Y.
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after
liver resection.
Cancer Science
2014;105(8):1002–1007.
DOI: 10.1111/cas.12453.
Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y.
Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for
metastatic colorectal cancer.
Anticancer Research
2013;33(1):309–316.
URL: http://ar.iiarjournals.org/content/33/1/309.
Horita Y, Yamada Y, Kato K, Hirashima Y, Akiyoshi K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada
Y.
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic
colorectal cancer: AVASIRI trial.
International Journal of Clinical Oncology
2012;17(6):604–609.
DOI: 10.1007/s10147-011-0331-2.
Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato K.
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line
treatment of patients with metastatic colorectal cancer.
Investigational New Drugs
2012;30(5):2026–2031.
DOI: 10.1007/s10637-011-9779-1.
Fujie H, Niu K, Ohba M, Tomioka Y, Kitazawa H, Nagashima K, Ohrui T, Numasaki M.
A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung
microvascular endothelial cells.
Inflammation
2012;35(3):1119–1131.
DOI: 10.1007/s10753-011-9419-0.
Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, Masutomi K.
Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for
esophageal carcinoma.
Cancer Science
2012;103(2):233–238.
DOI: 10.1111/j.1349-7006.2011.02142.x.
Tanai C, Nakajima TE, Nagashima K, Kato K, Hamaguchi T, Yamada Y, Muro K, Shirao K, Kunitoh H,
Matsumura Y, Yamamoto S, Shimada Y.
Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a
randomized clinical chemotherapy trial.
Journal of Oncology Practice
2011;7(3):148–153.
DOI: 10.1200/JOP.2010.000106.
Hashimoto K, Takashima A, Nagashima K, Okazaki S, Nakajima TE, Kato K, Hamaguchi T, Yamada Y,
Shimada Y.
Progression-free survival in first-line chemotherapy is a prognostic factor in second-line
chemotherapy in patients with advanced gastric cancer.
Journal of Cancer Research and Clinical Oncology
2010;136(7):1059–1064.
DOI: 10.1007/s00432-009-0752-8.
Preprint(s)
Nagashima K, Noma H, Furukawa TA.
pimeta: an R package of prediction intervals for random-effects meta-analysis.
[arXiv:2110.07856]
Yuda S, Kato K, Sasaki Y, Takahashi N, Shoji H, Takashima A, Okita N, Honma Y, Iwasa S, Hamaguchi T,
Nagashima K, Boku N.
Risk factors for FN, mucositis and esophagitis of combination chemotherapy with docetaxel, cisplatin,
and 5-fluorouracil for esophageal cancer.
DOI: 10.21203/rs.3.rs-62898/v1.
[R] gstest Package
(Generalized Two-Sample Kolmogorov-Smirnov Test for Right-Censored Data)
[R] surrosurvo Package
(Evaluation of Individual-Level Surrogacy for Survival and Ordinal Endpoints)
[R] RevGadgets Package
as a contributor (postprocessing gadgets for output generated by RevBayes; CRAN Task View: Phylogenetics)
[R] pimeta Package
(prediction intervals for random-effects meta-analysis; Nagashima K, et al. Stat Methods Med Res
2019; CRAN Task View: MetaAnalysis)
Kimura R, Nomura S, Nagashima K, Sato Y. A comparison of asymptotic and re-randomization tests under
non-proportional hazards scenarios with minimization method. The 44th Annual Conference of the
International Society for Clinical Biostatistics (ISCB 44), Aug. 30, 2023, Milan, Italy.
Nagashima K. pimeta: Prediction Intervals for Random-Effects Meta-Analysis. Evidence Synthesis and
Meta-Analysis in R Conference (ESMARConf 2023), Mar. 27–31, 2023, Virtual. (Invited Lecture)
Noma H, Nagashima K. Improved Monte Carlo inference methods for network meta-analysis. The 12th
International Conference of the ERCIM WG on Computational and Methodological Statistics
(CMStatistics 2019), Dec. 15, 2019, London, UK. (Poster) [Abstract]
Hamaguchi Y, Noma H, Nagashima K. Frequentist performances of the Bayesian prediction intervals for
random effects meta-analysis. 40th Annual Conference of the International Society for Clinical
Biostatistics (ISCB 40), Jul. 14–18, 2019, Leuven, Belgium. (Poster)
Noma H, Nagashima K. Asymptotic behaviors of the Mantel–Haenszel estimators and their robust
variance estimators when the common effect assumptions are violated. ENAR 2016 Spring Meeting, Mar.
6–9, 2016; JW Marriott Austin, Texas. (Poster) [Abstract]
Noma H, Nagashima K. Asymptotic behaviors of the Mantel–Haenszel estimators under the common
effect assumptions violated. Kyoto International Conference on Modern Statistics in the 21st
Century, Nov. 17–18, 2014; Kyoto International Conference Center, Kyoto.
Nagashima K, Sato Y. Information criterion for Firth-type penalized partial likelihood in Cox
regression. The 27th International Biometric Conference, Jul. 6–11, 2014; Firenze Fiera,
Italy. (Poster) [Abstract]
Nagashima K, Sato Y, Hamada C. A high-speed method for population pharmacokinetic data analysis in
genome-wide pharmacogenomic studies. The 26th International Biometric Conference, Aug. 26–31,
2012; Kobe Internatioanl Conference Center Kobe, Japan. (Poster) [Abstract]
Nagashima K, Sato Y, Hamada C. Studentized modified maximum contrast method for unequal sample sizes
in pharmacogenomics studies. The 25th International Biometric Conference, Dec. 5-10, 2010; Federal
University of Santa Catarina, Florianópolis, SC, Brazil. [Abstract]
Sato Y, Laird NM, Kato R, Nagashima K, Hamada C, Yoshimura I, Sakamoto H, Yoshida T. Modified
maximum contrast method to detect pharmacokinetics-related genes in pharmacogenomics studies. The 28th
Annual Conference of the International Society for Clinical Biostatistics (ISCB 28), Aug. 2, 2007,
Alexandroupolis, Greece.
Medical Researches
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience PC, Aparicio T,
Piessen G, van der Zijden CJ, Mostert B, Wijnhoven BPL, Tsushima T, Takeuchi H, Kato K, Kitagawa Y.
Surrogacy between pathological complete response and overall survival: An individual patient data
analysis of eight RCTs on neoadjuvant treatment plus surgery for esophageal cancer. ASCO 2025
Gastrointestinal Cancers Symposium, Jan. 23–25, 2025; Moscone West Building, San Francisco, CA.
(Poster)
[Abstract]
Inamoto R, Ogura N, Onishi M, Kito Y, Nagashima K, Furuta M, Machida N, Shoji H, Takahashi N.
Correlation between immune-related adverse events and clinical outcomes in patients treated with
first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A
multi-center retrospective study in Japan. ASCO 2025 Gastrointestinal Cancers Symposium, Jan.
23–25, 2025; Moscone West Building, San Francisco, CA. (Poster)
[Abstract]
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Takeuchi M, Hirata K, Tsugaru K, Yamamoto S,
Nomura M, Tsushima T, Takeuchi H, Kato K, Kitagawa Y. Investigation of synergistic effects in trials
of combination therapies with immune-checkpoint inhibitors in advanced gastric or gastroesophageal
junction cancer. ASCO 2025 Gastrointestinal Cancers Symposium, Jan. 23–25, 2025; Moscone West
Building, San Francisco, CA. (Poster)
[Abstract]
Onishi M, Ogura N, Inamoto R, Kito Y, Nagashima K, Takahashi N, Furuta M, Shoji H, Machida N.
Correlation between PD-L1 CPS and clinical outcomes in patients treated with first-line nivolumab plus
chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center retrospective
study in Japan. ASCO 2025 Gastrointestinal Cancers Symposium, Jan. 23–25, 2025; Moscone West
Building, San Francisco, CA. (Poster)
[Abstract]
Tsushima T, Yamamoto S, Kato K, Daiko H, Hara H, Kojima T, Abe T, Tsubosa Y, Kawakubo H, Yoshii T,
Fujita T, Kadowaki S, Matsuda S, Nagashima K, Aoki K, Yachida S, Kitagawa Y. Efficacy of neoadjuvant
CF or DCF, FLOT plus nivolumab for resectable locally advanced esophageal squamous cell carcinoma
(JCOG1804E: FRONTiER). The 20th ISDE World Congress for Esophageal Diseases, Sep 22–24, 2024;
Edinburgh International Convention Centre (EICC), in Edinburgh, Scotland. (Poster) [Abstract]
Takahashi N, Hara H, Nagashima K, Hirata K, Masuishi T, Matsumoto T, Kawakami H, Yamazaki K, Hironaka
S, Boku N, Muro M. Randomized phase II trial of trifluridine/tipiracil plus ramucirumab versus
trifluridine/tipiracil for pre-treated patients with advanced gastric or gastroesophageal junction
adenocarcinoma (RETRIEVE study, WJOG15822G). ESMO Gastrointestinal Cancers Congress 2024, Jun.
26–29 2024; ICM-International Congress Center of the Munich Messe, Munich, Germany. (Poster) [Abstract]
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Takeuchi M, Hirata K, Yamamoto S, Nomura M,
Tsushima T, Takeuchi H, Kato K, Kitagawa Y. Investigation of synergistic effects in trials of
combination therapies with immune-checkpoint inhibitors in advanced esophageal squamous cell
carcinoma. ESMO Gastrointestinal Cancers Congress 2024, Jun. 26–29 2024;
ICM-International Congress Center of the Munich Messe, Munich, Germany. (Poster) [Abstract]
Muto M, Nomura M, Sakanaka K, Shimizu J, Ohashi S, Watanabe A, Katada C, Amanuma Y, Minashi K, Kato K,
Kojima T, Nagashima K, Kim I, Tada H, Nakakura A, Sasaki H. Effect of nivolumab combined with
definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic
subtype could be its biomarker—The NOBEL trial. 2024 ASCO Annual Meeting, May 29– Jun. 3, 2023;
McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Kudo-Saito C, Boku N, Shoji H, Imazeki H, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y,
Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Aoki K, Muro K. IL33-ST2 axis as a diagnostic
and therapeutic biomarker in nivolumab therapy for advanced gastric cancer. 2024 ASCO Annual Meeting,
May 29– Jun. 3, 2023; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Hirano H, Yamada Y, Nagashima K, Hiraoka N, Sekine S, Takahashi N, Azuma M, Iwasa S, Kanato K, Machida
N, Kinoshita T, Hata H, Kawakami H, Takahari D, Ojima T, Kadowaki S, Boku N, Kurokawa Y, Terashima M,
Yoshikawa T. Impact of PD-L1 expression on survival in patients with unresectable/recurrent gastric
cancer receiving first-line chemotherapy without immune checkpoint inhibitors. ASCO 2024
Gastrointestinal Cancers Symposium, Jan. 18–20, 2024; Moscone West Building, San Francisco, CA.
(Poster) [Abstract]
Okui J, Nagashima K, Matsuda S, Sato Y, Okamura A, Kawakubo H, Muto M, Kakeji Y, Kono K, Takeuchi H,
Watanabe M, Doki Y, Bamba T, Fukuda T, Fujiwara H, Sato S, Noma K, Miyata H, Fujita T, Kitagawa Y.
Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma:
Nationwide real-world data from Japan. ASCO 2024 Gastrointestinal Cancers Symposium, Jan. 18–20,
2024; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Shimozaki K, Nakayama I, Takahari D, Nagashima K, Yoshino K, Fukuda K, Fukuoka S, Osumi H, Ogura M,
Wakatsuki T, Ooki A, Shinozaki E, Chin K, Yamaguchi K. Efficacy and safety of trastuzumab deruxtecan
and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A
single-institution retrospective study. ASCO 2024 Gastrointestinal Cancers Symposium, Jan.
18–20, 2024; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Yoshii T, Yamamoto S, Kato K, Daiko H, Hara H, Kojima T, Abe T, Tsubosa Y, Kawakubo H, Fujita T,
Kadowaki S, Tsushima T, Matsuda S, Nagashima K, Aoki K, Yachida S, Kitagawa Y. FRONTiER: A feasibility
trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma
(JCOG1804E)—Primary safety and short-term efficacy results for cohort E. ASCO 2024 Gastrointestinal
Cancers Symposium, Jan. 18–20, 2024; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kudo-Saito C, Boku N, Shoji H, Imazeki H, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y,
Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Aoki K, Muro K. The FSTL1-DIP2A axis as a
promising target in the anti-PD1 therapy of advanced gastric cancer. SITC 38th Annual Meeting (SITC
2023), Nov. 1–5, 2023; San Diego Convention Center, San Diego, CA. [Abstract]
Takahari D, Shoji H, Ooki A, Hirano H, Okita NT, Nagashima K, Adachi J, Yamaguchi K, Kato K, Boku N. A
phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to
platinum (NCCH-1811). ESMO Congress 2023, Oct. 20–24, 2023; IFEMA Madrid, Madrid, Spain.
(Poster) [Abstract]
Yamamoto K, Hirose T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T,
Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Sawada R, Otsu S, Shinozaki K,
Nagashima K, Shimada Y. First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT
mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and
Rectum. ESMO Congress 2023, Oct. 20–24, 2023; IFEMA Madrid, Madrid, Spain.
(Poster) [Abstract]
Hirose T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima
H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Sawada R, Otsu S, Shinozaki K, Nagashima K, Shimada Y.
Tumor response as a predictor of survival for RAS-WT left-sided mCRC administered first-line
molecularly targeted drugs: An observational study by the Japanese Society for Cancer of the Colon and
Rectum. ESMO Congress 2023, Oct. 20–24, 2023; IFEMA Madrid, Madrid, Spain.
(Poster) [Abstract]
Kashiro A, Kobayashi M, Oh T, Nagashima K, Takeuchi K, Nara S, Hijioka S, Morizane C, Kikuchi S, Kato
S, Kato K, Ochiai H, Obata D, Konishi H, Matsuyama K, Kutsumi H, Honda K. Clinical development of a
blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. European
Pancreatic Club 2023, Jun. 28–Jul. 1 2023; Congress Centrum Alpbach, Alpbach, Austria. (Poster)
[Abstract]
Yamamoto K, Hirose T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T,
Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Sawada R, Otsu S, Shinozaki K,
Nagashima K, Shimada Y. First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT
mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and
Rectum. ESMO World Congress on Gastrointestinal Cancers 2023, Jun. 28–Jul. 1 2023;
Centre de Convencions Internacional de Barcelona, Barcelona, Spain. (Poster) [Abstract]
Muto M, Minashi K, Yano T, Amanuma Y, Ishihara R, Watanabe A, Katada C, Yamatsuji T, Matsushima K,
Doyama H, Ando T, Nishimura Y, Sakanaka K, Tsunoda S, Ohashi S, Shimizu J, Tada H, Uozumi R, Nagashima
K, Sasaki H. Expression molecular subtype as a predictor of outcomes of chemoradiotherapy for
esophageal cancer. 2023 ASCO Annual Meeting, Jun. 2–6, 2023; McCormick Place, Chicago, Illinois.
(Poster) [Abstract]
Yamada Y, Kamada A, Kabeya Y, Yoshida S, Harada H, Urakawa N, Kanaji S, Nakamura Y, Nagashima K,
Takeuchi H, Doki Y, Kitagawa Y, Kodera Y, Kakeji Y. Development of an artificial intelligence
algorithm for adjuvant chemotherapy based on a nationwide registry of patients with gastric cancer by
the Japanese Gastric Cancer Association (JGCA). 2023 ASCO Annual Meeting, Jun. 2–6, 2023;
McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Tsugaru K, Boku N, Kudo-Saito C, Shoji H, Imazeki H, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T,
Okano N, Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Aoki K, Muro K. LAG3-related factors to predict
response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study). ASCO 2023
Gastrointestinal Cancers Symposium, Jan. 19–21, 2023; Moscone West Building, San Francisco, CA.
(Poster) [Abstract]
Yano T, Amanuma Y, Minashi K, Komatsu M, Nagashima K, Shimizu J, Ishihara R, Watanabe A, Yamatsuji
T, Matsushima K, Doyama H, Ando T, Nishimura Y, Sasaki H, Muto M. Association between endogenous
subtype classification for esophageal squamous cell carcinoma and outcome of chemoradiotherapy. The
18th ISDE World Congress for Esophageal Diseases, Sep 26–28, 2022; Virtual. (Poster) [Abstract]
Oka H, Nagashima K, Nishi H, Kumai Y, Iijima H, Okami K, Shimizu Y, Kano S, Ito K, Yamazaki T,
Takahashi H, Oridate N, Yokota T, Koyama T, Kiyota N, Kato K, Kadowaki S, Honma Y. Clinical outcomes
in patients with recurrent or metastatic head and neck squamous cell carcinoma after
failure of platinum and nivolumab: A multicenter retrospective study. ESMO Congress 2022,
Sep. 9–13, 2022, Paris, France. (Poster) [Abstract]
Boku N, Kudo-Saito C, Imazeki H, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T,
Okano N, Narita Y, Yamamoto Y, Kizawa R, Nagashima K, Aoki K, Muro K. Prognostic impact of myeloid
subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study). ESMO Congress 2022,
Sep. 9–13, 2022, Paris, France. (Poster) [Abstract]
Shoji H, Boku N, Kudo-Saito C, Nagashima K, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki
T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Imazeki H, Aoki K, Muro K. Profiling of myeloid cells
associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study).
ESMO Congress 2022, Sep. 9–13, 2022, Paris, France. (Poster) [Abstract]
Kobayashi T, Sato Y, Nishiumi S, Kodama Y, Nagashima K, Honda K. Prospective study of plasma
apolipoprotein A2-ATQ/AT to screen for high-risk individuals of pancreatic cancer. European Pancreatic
Club 2022, Jun. 22–25 2022, Kiev, Ukraine (virtual). [Abstract]
Yamada Y, Kobayashi H, Nagashima K, Sugihara K. Effect of adjuvant chemotherapy in patients with
stage III colon cancer based on the Multi-Institutional Registry of Large Bowel Cancer in Japan.
2022 ASCO Annual Meeting, Jun. 3–7, 2022; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Kadowaki S, Aoki M, Suzuki T, Takahashi N, Shirasu H, Ando T, Yamamoto Y, Kawakami K, Kito Y,
Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Akiyoshi K, Baba E, Makiyama A, Nakashima K,
Sugimoto N, Nagashima K, Boku N. Association of disease progression pattern during third-line
chemotherapy with nivolumab with poor prognosis in advanced gastric cancer: A multicenter
retrospective study in Japan. ASCO 2022 Gastrointestinal Cancers Symposium, Jan. 20–22, 2022;
Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Matsuda S, Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Kawakubo H, Nagashima K,
Aoki K, Yachida S, Kitagawa Y. FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or
DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Short-term results for
cohorts C and D. ASCO 2022 Gastrointestinal Cancers Symposium, Jan. 20–22, 2022; Moscone West
Building, San Francisco, CA. (Poster) [Abstract]
Shimozaki K, Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y,
Matsumoto T, Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Hamamoto Y, Takaishi
H, Muro K. WJOG13219G: Triplet versus doublet in patients with previously untreated
BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world
data analysis (BRACELET study). ASCO 2022 Gastrointestinal Cancers Symposium, Jan. 20–22,
2022; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi
T, Ishidoya S, Shimoda J, Sato H, Mituzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K,
Habuchi T. Changes in the conditional net survival and dynamic prognostic factors in patients with
newly diagnosed metastatic prostate cancer. The 2021 AUA Annual Meeting 2021, Sep. 10–13,
2021; Virtual. (Poster) [Abstract]
Kumagai K, Yagi S, Yamaguchi T, Nagashima K, Nomura T, Watanabe M, Makuuchi R, Kawakami K, Otsuka S,
Matsushima T, Kadowaki S, Haruta S, Cho H, Yamada T, Kakihara N, Imai Y, Fukunaga H, Saeki Y, Kanaji
S, Boku N, Goto M. The efficacy of chemotherapy for gastric cancer with early recurrence during or
after adjuvant S-1. ESMO Congress 2022, Jun. 30–Jul. 3, 2021, Virtual. (Poster) [Abstract]
Ito T, Takashima A, Shirasu H, Yukami H, Uetake H, Tsuda M, Sudo T, Moriwaki T, Sugimoto N, Ojima H,
Takii Y, Yasui H, Ezaki T, Tsuji A, Goto M, Saruta M, Ootsu S, Shinozaki K, Nagashima K, Shimada Y.
Predictive role of tumor location in 1st-line treatment of colorectal cancer: a multicenter
retrospective study of JSCCR. 2021 the Japanese Society of Medical Oncology Annual Meeting, Feb. 20,
2021; Virtual.
Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Kawakubo H, Fujita T, Fukuda T,
Kadowaki S, Tsushima T, Hamamoto Y, Nagashima K, Aoki K, Mizoguchi Y, Kitano S, Yachida S, Shiba S,
Kitagawa Y. FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for
locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.
ASCO 2021 Gastrointestinal Cancers Symposium, Jan. 15–17, 2021; Virtual. (Poster) [Abstract]
Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi
T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K,
Habuchi T, Michinoku Japan Urological Cancer Study Group. Changes in conditional net survival and
dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer. ASCO 2020
Genitourinary Cancers Symposium, Feb. 13–15, 2020; Moscone West Building, San Francisco, CA.
(Poster) [Abstract]
Suzuki T, Aoki M, Shirasu H, Takahashi N, Nakatsuka R, Ando T, Kito Y, Yamamoto Y, Kawakami K,
Matsumoto T, Shimozaki K, Nagase M, Yamaguchi T, Negoro Y, Tamura T, Amanuma Y, Esaki T, Miura Y,
Nagashima K, Boku N. Hyperprogressive disease during nivolumab chemotherapy in metastatic gastric
cancer: multicenter retrospective study in Japan. ASCO 2020 Gastrointestinal Cancers Symposium, Jan.
23–25, 2020; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Nakayama I, Shoji H, Hara H, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Takahari D, Miyamoto
T, Boku N, Kato K. Correlation of tumor mutation with efficacy in patients with gastric cancer who
received nivolumab and ramucirumab combination therapy. ASCO 2020 Gastrointestinal Cancers
Symposium, Jan. 23–25, 2020; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Honda K, Kobayashi T, Sato Y, Nishiumi S, Okaya S, Takeuchi K, Nagashima K, Yoshida M.
Stratification of pancreatic cancer risk in the general population using an apolipoprotein A2
isoform blood test. 50th Anniversary Meeting American Pancreatic Association & Japan Pancreas
Society, Nov. 7, 2019, Maui, Hawaii. (Poster) [Abstract]
Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Nagashima K, Kitagawa K. FRONTiER:
A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal
carcinoma. ESMO Congress 2019, Sep. 29, 2019, Barcelona, Spain. (Poster) [Abstract]
Hiramoto S, Kikuchi A, Hori T, Yoshioka A, Nagashima K. Associations between primary cancer site,
metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal
cancer patients at end-of-life. ESMO World Congress on Gastrointestinal Cancer 2019, Jul. 3–6,
2019; Centre de Convencions Internacional de Barcelona, Barcelona, Spain. (Poster) [Abstract]
Hiramoto S, Nagashima K, Hori T, Kikuchi A, Yoshioka A. Association between prognosis and
discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received
end-of-life chemotherapy. ESMO World Congress on Gastrointestinal Cancer 2019, Jul. 3–6, 2019;
Centre de Convencions Internacional de Barcelona, Barcelona, Spain. (Poster) [Abstract]
Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H,
Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse
events and prognosis in patients with gastric cancer treated with nivolumab. 2019 ASCO Annual
Meeting, May 31–Jun. 4, 2019; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Hara H, Shoji H, Takahari D, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N,
Kato K. Phase I/II study of ramucirumab plus nivolumab in patients in second line treatment for
advanced gastric adenocarcinoma (NivoRam study). ASCO 2019 Gastrointestinal Cancers Symposium, Jan.
17–19, 2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kumagai K, Yamaguchi T, Takashima A, Nagashima K, Kano Y, Terashima M, Yabusaki H, Nishikawa K,
Tanabe K, Yunome G, Kawachi Y, Yamada T, Fukunaga H, Kinoshita T, Watanabe M, Taniguchi H, Sakamoto
T, Ishiyama K, Boku N. Comparison between S-1 monotherapy and S-1 plus cisplatin as post-operative
chemotherapy after R0 resection for stage IV gastric cancer patients with oligo-metastasis: a
multicenter retrospective study. ASCO 2019 Gastrointestinal Cancers Symposium, Jan. 17–19,
2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Ogasawara S, Ueshima K, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura
T, Kuroda H, Ohki T, Nagashima K, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M.
Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular
carcinoma: a Japanese multi-center large cohort study. ASCO 2019 Gastrointestinal Cancers Symposium,
Jan. 17–19, 2019; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kita S, Takashima A, Hirano H, Aoki M, Imazeki H, Ishikawa M, Shoji H, Honma Y, Iwasa S, Okita N,
Kato K, Nagashima K, Boku N. CT image features of peritoneal metastasis and outcomes of the advanced
gastric cancer patients receiving second-line chemotherapy. ESMO Asia 2018 Congress, Nov. 24, 2018;
Suntec Singapore Convention & Exhibition Centre, Singapore. [Abstract]
Sato Y, Kobayashi T, Nishiumi S, Okaya S, Yoshida M, Kodama Y, Nagashima K, Honda K. Usefulness of
the first screening using apolipoprotein A2 isoforms as the enrichment strategy for pancreatic
cancer and its risk diseases. ESMO 2018 Congress, Oct. 19–23, 2018; Messe Munich, Munich,
Germany. [Abstract]
Misawa S, Sato Y, Katayama K, Nagashima K, Sekiguchi Y, Amino H, Suichi T, Kuwabara S. The safety
and efficacy of thalidomide treatment prior to autologous stem-cell transplantation in POEMS
syndrome. 2018 Peripheral Nerve Society Annual Meeting, Jul. 21–25, 2018; Baltimore, Maryland.
(Poster) [Abstract]
Esaki T, Shoji H, Takahari D, Hara H, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N,
Kato K. Preliminary result of p1/2 study of ramucirumab plus nivolumab in patients with pretreated
advanced gastric carcinoma. 2018 the Japanese Society of Medical Oncology Annual Meeting, Jul.
19–21, 2018; Kobe Convention Center, Kobe. [Abstract]
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yokoh H,
Kobayashi A, Onishi S, Kobayashi K, Ogino J, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M,
Ide K, Ide S, Baba Y, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Takemoto M, Yokote K.
Comparing the effects of ipragliflozin and metformin on visceral fat reduction in patients with type
2 diabetes inadequately controlled with sitagliptin–a prospective, multicenter, blinded-endpoint,
randomized controlled study in Japan (PRIME-V study). American Diabetes Association, the 78th
Scientific Sessions, Jun 22–26, 2018; Orange County Convention Center, Orlando, FL. [Abstract]
Takahari D, Shoji H, Hara H, Esaki T, Machida N, Nagashima K, Aoki K, Honda K, Miyamoto T, Boku N,
Kato K. Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with
previously treated advanced gastric adenocarcinoma (NivoRam study). 2018 ASCO Annual Meeting, Jun
1–5, 2018; McCormick Place, Chicago, Illinois. (Poster) [Abstract]
Aizawa M, Yamaguchi T, Takashima A, Nagashima K, Ema A, Yuasa Y, Haruta S, Taniguchi H, Kobayashi D,
Nishikawa K, Yunome G, Takagi M, Niwa H, Yamada T, Hato S, Fukagawa T, Boku N, Katai H. Comparison
of S-1 and S-1 plus cisplatin as post-operative chemotherapy for gastric carcinoma with peritoneal
lavage cytology positive or localized peritoneum metastasis: A multicenter retrospective study. ASCO
2018 Gastrointestinal Cancers Symposium, Jan. 18–20, 2018; Moscone West Building, San
Francisco, CA. (Poster) [Abstract]
Makuuchi R, Yamaguchi T, Takashima A, Nagashima K, Yamada T, Kinoshita T, Hata H, Kawachi Y,
Kawabata R, Tsuji T, Hirabayashi N, Sakamoto T, Inada T, Ishiyama K, Fukagawa T, Boku N, Katai H.
The impact of pre-operative chemotherapy in patients with peritoneal lavage cytology positive or
localized peritoneum metastasis for gastric cancer: A multicenter retrospective study. ASCO 2018
Gastrointestinal Cancers Symposium, Jan. 18–20, 2018; Moscone West Building, San Francisco,
CA. (Poster) [Abstract]
Iwase T, Sangai T, Nagashima T, Sakakibara M, Fujimoto H, Sawabe Y, Nagashima K, Otsuka M. The
quality and quantity of visceral fat tissue are associated with insulin resistance and survival
outcome after chemotherapy for patients with early-stage breast cancer. 2017 San Antonio Breast
Cancer Symposium, Dec 5–9, 2017; Gonzales Convention Center, San Antonio, TX. (Poster) [Abstract]
Misawa S, Katayama K, Sato Y, Nagashima K, Sekiguchi Y, Suichi T, Amino H, Hanaoka H, Kuwabara S.
Pre-transplant induction thalidomide treatment in poems syndrome: An open-labell phase II clinical
trial. The XXIII World Congress of Neurology (WCN 2017), Sep 16–21, 2017; International
Conference Center Kyoto, Kyoto. [Abstract]
Suichi T, Misawa S, Nagashima K, Sekiguchi Y, Shibuya K, Watanabe K, Kuwabara S. Safety and efficacy
of lenalidomide for intractable/recurrent poems syndrome: An open label pilot study. The XXIII World
Congress of Neurology (WCN 2017), Sep 16–21, 2017; International Conference Center Kyoto,
Kyoto. [Abstract]
Shoji H, Miyamoto H, Hara H, Takahari D, Machida N, Esaki T, Nagashima K, Aoki K, Honda K, Nagata Y,
Miyamoto T, Boku N, Kato K. A phase 1/2 study of ramucirumab plus nivolumab in patients with
previously treated advanced gastric adenocarcinoma. ESMO 2017 Congress, Sep. 8–12, 2017; IFEMA
- Feria de Madrid, Spain. (Poster)
Sasaki Y, Kato K, Hirano H, Shoji H, Honma Y, Iwasa S, Takashima A, Hamaguchi T, Nagashima K, Boku
N. Evaluation of α-1-acid glycoprotein as a prognostic marker and as a predictive biomarker
for severe neutropenia induced by docetaxel in esophageal carcinoma patients. AACR Annual Meeting
2017; Apr. 1–5, 2017; Walter E. Washington Convention Center, Washington, D. C. (Poster) [Abstract]
Terazawa T, Iwasa S, Sasaki Y, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Hirano H, Honma
Y, Takashima A, Kato K, Hamaguchi T. A multicenter phase II study of combination therapy with oral
S-1 plus cisplatin in elderly patients with advanced gastric cancer. ASCO 2017 Gastrointestinal
Cancers Symposium, Jan. 19–21, 2017; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Tsushita N, Honma Y, Nagashima K, Miyamoto T, Nakamura S, Umezawa R, Ito Y, Shoji H, Takashima A,
Iwasa S, Kato K, Hamaguchi T, Itami J, Boku N. Risk factor analyses of severe cicatricial stricture
after chemoradiotherapy for stage II/III (T3) esophageal carcinoma. ASCO 2017 Gastrointestinal
Cancers Symposium, Jan. 19–21, 2017; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kato K, Kojima T, Ito Y, Igaki H, Daiko H, Onozawa M, Hamamoto Y, Matsushita N, Nagashima K, Katano
S. Feasibility study of neo-chemoradiotherapy for stage IB/II/III esophageal squamous cell
carcinoma: A 4-year follow up. 2016 the Japanese Society of Medical Oncology Annual Meeting, Jul.
28–30, 2016; Kobe Internatinal Conference Center & Kobe Internatinal Exhibition Hall,
Kobe. [Abstract]
Suzuki W, Ohyanagi F, Yanai T, Hashimoto H, Takashima A, Nakao M, Nakayama T, Iwasa S, Nagashima K,
Yamamoto N. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced
by cisplatin-based chemotherapy. 2016 the Japanese Society of Medical Oncology Annual Meeting, Jul.
28–30, 2016; Kobe Internatinal Conference Center & Kobe Internatinal Exhibition Hall,
Kobe.
Hashimoto H, Yanai T, Nagashima K, Okita NT, Horinouchi H, Takiguchi T, Ohyanagi F, Nakao M, Takeda
K, Nakayama T, Sakai H, Arai T, Minato K, Kogure Y, Harada D, Suzuki K, Boku N, Shimada Y, Iwasa S,
Yamamoto N. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced
by highly emetogenic chemotherapy with cisplatin. 2016 ASCO Annual Meeting, Jun 3–7, 2016;
McCormick Place, Chicago, Illinois. (Poster, J Clin Oncol
2016; 34(suppl): abstr 10111) [Abstract]HOT
Ohba A, Takashima A, Nishiuchi T, Honma Y, Iwasa S, Okita N, Kato K, Hamaguchi T, Nagashima K, Boku
N. Second-line chemotherapy with paclitaxel for elderly patients with advanced gastric cancer. ASCO
2016 Gastrointestinal Cancers Symposium, Jan. 21–23, 2016; Moscone West Building, San
Francisco, CA. (Poster) [Abstract]
Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Yoshitaka Honma Y, Iwasa S, Okita N,
Takashima A, Kato K, Yamada Y, Katayama N, Narikazu Boku N, Hamaguchi T, Heike Y. Immune status at
pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated
with first-line chemotherapy. 30th Annual Meeting and Associated Programs of the Society for
Immunotherapy of Cancer (SITC 2015), Nov. 4–8, 2015; Gaylord National Hotel & Convention
Center, National Harbor, Maryland. (Poster) [Abstract]
Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T,
Nagashima K, Okita N, Yamada Y. Impact of KRAS/NRAS mutation status on the outcomes of patients with
stage III colorectal cancer: Correlative study in NSAS-CC/RC. The 18th ECCO - 40th ESMO European
Cancer Congress, Sep. 25–29, 2015; Messe Wien Exhibition & Congress Centre, Vienna,
Austria. (Poster) [Abstract]
Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Ito A, Honma Y, Iwasa S,
Okita N, Takashima A, Kato K, Yamada Y, Boku N, Hamaguchi T. Association between the peripheral
immune status of granulocytic myeloid-derived suppressor cells and progression-free survival
chemotherapy. The 18th ECCO - 40th ESMO European Cancer Congress, Sep. 25–29, 2015; Messe Wien
Exhibition & Congress Centre, Vienna, Austria. (Poster) [Abstract]
Tada K, Shoji H, Kitano S, Nishimura T, Shimada Y, Nagashima K, Ito A, Honma Y, Iwasa S, Okita M,
Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Identification of an
immunological prognostic factor for metastatic colorectal cancer patients treated with first-line
oxaliplatin-based chemotherapy. The 18th ECCO - 40th ESMO European Cancer Congress, Sep.
25–29, 2015; Messe Wien Exhibition & Congress Centre, Vienna, Austria. (Poster) [Abstract]
Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Okita NT, Takashima A, Iwasa S, Kato K,
Hamaguchi T, Shimada Y, Boku N, Yamada Y. Imaging peritoneal metastasis of gastric cancer with
PET/CT and the radiotracer 18F-fluorothymidine (18F-FLT): Proof-of-concept
study. 2015 ASCO Annual Meeting, May 29–Jun. 2, 2015; McCormick Place, Chicago, Illinois.
(Poster discussion session) [Abstract]
Hirashima Y, Hanaoka T, Watanabe K, Nagashima K, Inagaki T, Nishikawa K, Hisamatsu Y, Morinaga R,
Otsu S, Kumamoto T, Shirao K. A prospective study to evaluate the usefulness of the clanging tuning
fork test and the nerve conduction velocity test for oxaliplatin-induced peripheral neuropathy. ASCO
2015 Gastrointestinal Cancers Symposium, Jan. 15–17, 2015; Moscone West Building, San
Francisco, CA. (Poster) [Abstract]
Yuda S, Kato K, Sasaki Y, Takahashi N, Shoji H, Takashima A, Okita NT, Honma Y, Iwasa S, Hamaguchi
T, Yamada Y, Nagashima K, Boku N. Risks of severe adverse events of docetaxel, cisplatin, and
5-fluorouracil (DCF) combination chemotherapy of esophageal cancer. ASCO 2015 Gastrointestinal
Cancers Symposium, Jan. 15–17, 2015; Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Kubo A, Yamada Y, Takahashi N, Nagashima K, Hashimoto H, Iwasa S, Honma Y, Okita N, Takashima A,
Kato K, Hamaguchi T, Hayashi Y, Shimada Y. Serum epiregulin is associated with prognosis and skin
toxicity on anti-EGFR antibody treatment in KRAS wild-type mCRC. The 73rd Annual Meeting of the
Japanese Cancer Association, Sep. 25–27, 2014; Pacifico Yokohama, Kanagawa. (Poster)
Kubo E, Kato K, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Nagashima K.
Comparison of the long-term toxicities with two different chemoradiotherapy for esophageal squamous
cell carcinoma. The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 17–19,
2014; Fukuoka.
Takahashi S, Ishiwada N, Hishiki H, Nagasawa K, Chang B, Nagashima K. Serotype distribution and drug
resistance of streptococcuspneumoniae isolated from children with community acquired pneumonia in
Japan. 13th International Congress on Pediatric Pulmonology, Jun. 26–29, 2014; Bruges,
Belgium. (Poster) [Abstract]
Iwasa S, Hamaguchi T, Nagashima K, Goto M, Okazaki S, Sasaki Y, Nagai Y, Asami C, Shimada Y.
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients
with advanced gastric cancer. ESMO 16th World Congress on Gastrointestinal Cancer, Jun. 25–28,
2014; Barcelona, Spain. (Poster) [Abstract]
Kato K, Hashimoto J, Ito Y, Nagashima K, Kojima T, Daiko H, Akimoto T, Hamamoto Y, Matsushita H,
Katano S, Hara H, Tanaka Y, Saito Y, Igaki H. Phase II study of neoadjuvant chemoradiotherapy with
cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous
cell carcinoma: A 2-year follow up. ASCO 2014 Gastrointestinal Cancers Symposium, Jan. 16–18,
2014; The Moscone West Building, San Francisco, CA. (Poster) [Abstract]
Goto A, Yamada Y, Iwasa S, Nagashima K, Yamaguchi T, Ichikawa Y, Yasui H, Kato K, Okita NT, Shimada
Y. S-1 and irinotecan versus 5-fluorouracil and leucovorin plus oxaliplatin with or without
bevacizumab in metastatic colorectal cancer: A pooled analysis of 4 phase II studies. The 17th ECCO,
38th ESMO, 32nd ESTRO, European Cancer Congress. Sep. 27–Oct. 1, 2013; Amsterdam. (Poster) [Abstract]
Hirashima Y, Hanaoka T, Watanabe K, Nagashima K, Nishikawa K, Morinaga R, Otsu S, Kumamoto T, Shirao
K. A prospective study to evaluate the usefulness of neurological test for oxaliplatin-induced
peripheral neuropathy. The 11th Annual Meeting of Japanese Society of Medical Oncology, Aug.
29–31, 2013; Tohoku University Centennial Hall, Sendai, Miyagi.
Kato K, Nakajima T, Ito Y, Katada C, Ishiyama H, Tokunaga S, Tanaka M, Hironaka S, Hashimoto T, Ura
T, Kodaira T, Yoshimura K, Nagashima K, Ishikura S. Phase II study of concurrent chemoradiotherapy
with elective nodal irradiation for stage II-III esophageal carcinoma, modified RTOG regimen. The
9th Annual Meeting of Japanese Society of Medical Oncology, Jul. 21–23, 2011; Pacifico
Yokohama, Yokohama, Kanagawa.
Okita NT, Kato K, Tokunaga S, Esaki T, Baba E, Takiuchi H, Mizunuma N, Kato T, Inaba Y, Kanemitsu Y,
Yasui H, Fuse N, Hamaguchi T, Yamada Y, Shimada Y, Nagashima K. Dose Initial tumor size affect
bevacizumab efficay in 1st-line FOLFOX treatment for metastatic CRC? The 9th Annual Meeting of the
Japanese Society of Medical Oncology, Jul. 21–23, 2011; Pacifico Yokohama, Yokohama, Kanagawa.
(Poster)
Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Nagashima K, Nakajima TE,
Hamaguchi T, Shimada Y, Shirao K. New analysis of the hypertension mechanism in bevacizumab-treated
patients using 3-Tesla dynamic contrast-enhanced magnetic resonance imaging. ASCO 2011
Gastrointestinal Cancers Symposium, Jan. 20–22, 2011; The Moscone West Building, San
Francisco, CA. (Poster) [Abstract]
Akiyoshi K, Yamada Y, Hirashima Y, Horita Y, Kato K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada
Y. Phase II trial of the second-line 5-fluorouracil ℓ-leucovorin/irinotecan (FOLFIRI) and
bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. ASCO 2010
Gastrointestinal Cancers Symposium, Jan. 22–24, 2010; The Orlando World Center Marriott,
Orlando, Florida. (Poster)
Yoshida H, Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato
K. Phase II study of the "stop and go" modified FOLFOX6 regimen with bevacizumab for first-line
patients with metastatic colorectal cancer. ASCO 2010 Gastrointestinal Cancers Symposium, Jan.
22–24, 2010; The Orlando World Center Marriott, Orlando, Florida. (Poster)